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The latest fi gures from the National Drug-Related 
Deaths Index (NDRDI) show that a total of 736 
deaths in Ireland during 2016 were linked to drug 
use.1,2 The NDRDI reports on poisoning deaths (also 
known as overdose), which are due to the toxic 
eff ect of a drug or combination of drugs, and on 
non-poisonings, which are deaths as a result of 
trauma, such as hanging, or medical reasons, such 
as cardiac events, among people who use drugs.
Key fi ndings of the report are:
• Prescription drugs contribute to the majority of poisonings and 
were implicated in 258 or three in every four poisonings during 
2016.
• Taking a cocktail of drugs (polydrugs) continues to be a 
signifi cant factor in poisoning deaths.
• Alcohol remains the main drug implicated in poisoning deaths, 
alone or with other drugs.
• Hanging is the main cause of non-poisoning deaths. 
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In brief
While research and health-related issues have 
been given some attention in the public debate 
around Brexit, they have struggled to gain 
attention in the heated discussion around trade, 
free movement, and judicial oversight. A recent 
paper1 by a group of public health academics has 
attempted to highlight the damaging effect that 
the severing of links with agencies such as the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) and Europol will have on 
the UK’s capacity to deal with the consequences 
of illicit drug use. They point out that continued 
access to EU-generated information and 
intelligence is not guaranteed in a post-Brexit 
situation.
The recent increase in cocaine-related deaths and the 
dangers posed by organised crime’s participation in the 
distribution of extremely dangerous synthetic opioids 
underline the importance of access to the timely and 
accurate data made available through participation in the 
EMCDDA’s network of national drug monitoring centres. 
Recent advances in tackling drug-related organised crime 
in Scotland through multiagency collaboration has been 
dependent on access to good-quality epidemiological and 
supply information. As the trade in illicit drugs is by its nature 
international and largely hidden, linking this information to 
the wider European picture is essential if decisions are to be 
based on evidence.
The EU Early Warning System on new psychoactive 
substances has been highly successful at detecting new 
drugs, accurately describing their characteristics and 
potential dangers, and sharing this information effectively 
so that the knowledge gained through this system can 
inform the response of all member states. The recent re-
establishment of Ireland’s Early Warning and Emerging Trends 
network allow us to contribute and learn from this rich 
source of information.
Through its participation in the EMCDDA, the UK has made 
a significant contribution to our understanding of the 
European drugs situation and its implications for public 
health and security and the capacity of member states 
to respond quickly to new developments, identify and 
implement responses supported by evidence, and evaluate 
policies and strategies. Severing this link with European 
institutions may well have public health and security 
consequences and cause lasting damage to the UK’s ability to 
manage these harms.
1 Roman-Urrestarazu A, Yang J, Robertson R, McCallum A, Gray C, 
McKee M and Middleton J (2019) Brexit threatens the UK’s ability 
to tackle illicit drugs and organised crime: what needs to happen 
now? Health Policy, 123(6): 521–25.
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In the 13-year period from 2004 to 2016 inclusive, a total of 
8,207 drug-related deaths were recorded by the NDRDI. Of 
these deaths, 4,597 (56%) were due to poisoning and 3,610 
(44%) were non-poisoning deaths.
There were 736 deaths in 2016, similar to the number 
reported in 2015 (735) (see Table 1). Many of these deaths were 
premature, with one-half of all deaths in 2016 aged 42 years 
or younger. Three in four (549) of all deaths in 2016 were male. 
In 2016 alone, 21,300 potential life years3 were lost because of 
drug-related deaths (see Figure 1).
Deaths in 2016 among people who inject drugs 
People who were injecting at the time of the incident that led 
to their death represented 5% (34 deaths) of all drugs-related 
deaths in 2016. The majority were male, involved opiates (85%) 
and two-thirds (65%) occurred in Dublin city (see Figure 2). 
Poisoning deaths in 2016
The annual number of poisoning deaths decreased slightly from 
365 in 2015 to 354 in 2016 (see Table 1). As in previous years, the 
majority (69%) were male. The median age of those who died 
was 42 years. 
Drug-related deaths, 2004–2016 
continued
Key findings of poisoning deaths in 2016:
• The number of deaths involving alcohol increased by 18% 
from 112 in 2015 to 132 in 2016. Alcohol was implicated in 
over one in every three poisoning deaths (37%) and alcohol 
alone was responsible for 16% of all poisoning deaths.
• Opiates were the main drug group implicated in poisonings; 
methadone was implicated in almost one-third (29%) of 
poisonings, while heroin-related deaths decreased for the 
third year in a row from 96 deaths in 2014 to 72 in 2016 (see 
Figure 3).
• Prescription and/or over-the-counter drugs were 
implicated in seven in every 10 (73%) poisoning deaths.
       – Benzodiazepines were the most common prescription  
  drug group implicated. Diazepam was the most   
  common benzodiazepine-type drug and   
  was implicated in one in four (96; 27%) of poisonings.
       – Methadone was the most common single prescription  
  drug, implicated in 103 (29%) of poisonings.
       – Pregabalin (an anti-epileptic drug also prescribed   
  for neuropathic pain and generalised anxiety disorders)  
  was implicated in 65 deaths in 2016, an increase from 49  
  deaths in 2015, with a persistent rise from 14 deaths in  
  2013.
• Cocaine-related deaths decreased from 45 in 2015 to 41 in 
2016.
Table 1: Number of deaths, by year, NDRDI 2004–2016 (n=8207)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
All deaths (8207) 431 502 554 620 629 655 607 644 661 707 726 735 736
Poisonings (4597) 266 300 326 386 387 371 339 377 356 400 370 365 354
Non-poisonings (3610) 165 202 228 234 242 284 268 267 305 307 356 370 382
Figure 1: Infographic of all drug-related deaths in 2016
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Figure 2: Infographic of all deaths among people known to be injecting at time of death in 2016
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continued
Figure 3: Infographic of poisoning deaths in 2016
Polydrug poisonings in 2016
Taking a cocktail of drugs (polydrugs) can increase the risk of 
fatal overdose. The majority of poisoning deaths (62%) in 2016 
involved polydrugs, with an average of four different drugs 
taken (see Figure 4).
• 58% (77) of deaths where alcohol was implicated involved 
other drugs, mainly opiates.
• 88% (91) of deaths where methadone was implicated 
involved other drugs, mainly benzodiazepines.
• 81% (58) of deaths where heroin was implicated involved 
other drugs, mainly benzodiazepines.
• All diazepam-related deaths (96) involved other drugs.
Non-poisoning deaths in 2016
The number of non-poisoning deaths increased slightly with 
382 deaths in 2016 compared with 370 in 2015. Non-poisoning 
deaths are categorised as being due to either trauma (172 
deaths) or medical causes (210 deaths).
• The main causes of non-poisoning deaths categorised as 
trauma were hanging (93; 24%) and those categorised as 
medical were cardiac events (56; 15%).
• Three in every four (75%) people who died as a result of 
hanging had a history of mental health problems.
• The median age for deaths due to medical causes has 
increased from 38 years in 2004 to 46 years in 2016, which 
may indicate an ageing cohort of people who use drugs in 
Ireland.
Ena Lynn
1 Health Research Board (2019) National Drug-Related Deaths Index 
2004 to 2016 data. Dublin: Health Research Board.   
https://www.drugsandalcohol.ie/30174/ 
2 A number of infographics that outline key data are also available 
for download as well as tables outlining breakdown by county and 
DATFA (Drug and Alcohol Task Force Area). For further information, 
visit: www.drugsandalcohol.ie/30174 and www.hrb.ie/publications 
3 Potential life years lost was calculated by looking at the age of 
individuals who died in 2016 and what their life expectancy would 
have been based on their year of birth.
Figure 4: Evolution of polydrug poisonings, NDRDI 2004–2016 (n=4597)
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Political Declaration, the 2014 Joint Ministerial Statement on the 
review by CND,4 and the 2016 UNGASS outcome document.5 It 
also commits to deliver on the Sustainable Development Goals 
2030.
The declaration presents a bleak picture of the ‘persistent and 
emerging challenges related to the drug problem’, noting, for 
example, ‘record levels’ in the abuse, illicit cultivation, production, 
manufacture and trafficking of narcotic drugs and psychotropic 
substances. While these persistent challenges are seen by many 
commentators as an indication of a failure of the current policy 
framework to achieve the goals set out in the 2009 document, 
the members make an ongoing commitment ‘to actively 
promote a society free of drug abuse’.3 There is also a pledge 
to review progress in implementing the international drug policy 
commitments in 2029, with a mid-term review in 2024.
Responses to the Political Declaration
The declaration has drawn criticism from civil society 
stakeholders. It is seen to represent some progress towards a 
more health and human rights-based approach, especially in 
its commitment to the UNGASS outcomes document and the 
Sustainable Development Goals 2030. However, it is not deemed 
to have gone far enough in that direction and away from a more 
punitive approach. The International Drug Policy Consortium 
(IDPC) sees this and the ongoing commitment to the ‘damaging 
drug free goals’ to mean the declaration ‘has once again stifled 
progress in UN drug policy’.6 The Eurasian Harm Reduction 
Association (EHRA) expressed concern that by continuing to focus 
on a ‘society free of drug abuse’, this will result in the ongoing 
‘persecution of people who use drugs’ and is incompatible with 
ensuring basic human rights.7 The lack of any ‘genuine and honest 
evaluation’ of the impact of international policies on delivering 
on the targets as laid out in the 2009 Political Declaration was 
also heavily criticised.6 This was seen as indicative of a lack of 
willingness on the part of member states to admit that punitive 
and repressive policies have failed in the attempt ‘to eradicate the 
global illicit drug market’.6
Lucy Dillon
1  A blog of many of the sessions is available at:    
http://cndblog.org/; the full programme for the session is 
available at: https://www.unodc.org/documents/commissions/
CND/2019/2019_CND_PROGRAMME/Programme_CND_2019.pdf
2 United Nations Office on Drugs and Crime (UNODC) (2009) Political 
Declaration and plan of action on international cooperation 
towards an integrated and balanced strategy to counter the world 
drug problem. Vienna: UNODOC.    
https://www.drugsandalcohol.ie/30219/
3 UN Economic and Social Council (2019) Draft ministerial declaration 
on strengthening our actions at the national, regional and 
international levels to accelerate the implementation of our joint 
commitments to address and counter the world drug problem. 
Vienna: UNODOC. Available online at: https://undocs.org/E/
CN.7/2019/L.11
4 UNODOC (2014) Joint Ministerial Statement. 2014 high-level review 
by the Commission on Narcotic Drugs of the implementation by 
member states of the political declaration and plan of action on 
international cooperation towards an integrated and balanced 
strategy to counter the world drug problem. Vienna: UNODOC. 
https://www.drugsandalcohol.ie/24407/
5 UNODOC (2016) Outcome document of the 2016 United Nations 
General Assembly Special Session on the world drug problem: our 
joint commitment to effectively addressing and countering the world 
drug problem. Vienna: UNODOC. Available online at: https://www.
unodc.org/documents/postungass2016/outcome/V1603301-E.pdf
POLICY AND LEGISLATION 
Ministerial segment 
of 62nd session of 
Commission on 
Narcotic Drugs
The Commission on Narcotic Drugs (CND) is the governing body 
of the United Nations Office on Drugs and Crime (UNODC). 
Essentially, it is the central drug policymaking body of the United 
Nations (UN). It aims to provide member states and civil society 
with the opportunity to exchange expertise, experiences, 
and information on drug-related matters and to develop a 
coordinated response to the drug situation. Membership is made 
up of representatives from 53 UN member states, allowing for a 
spread of geographical representation. Ireland is not currently a 
member.
In March 2019, representatives from UN member states and civil 
society met in Vienna for the 62nd session of the CND. As well as 
plenary sessions, there were approximately 100 side events held.1 
However, a much-anticipated two-day ministerial segment took 
place at the start of the session; it is this element of the session 
that is the focus of this article.
Ministerial segment
The Political Declaration and plan of action on international 
cooperation towards an integrated and balanced strategy 
to counter the world drug problem was adopted by CND in 
2009.2 The Political Declaration includes measures to enhance 
international cooperation, identifies problems and areas requiring 
further action, as well as goals and targets in countering the 
world drug problem. The year 2019 was set as the target date 
for member states to ‘eliminate or reduce significantly and 
measurably’ five target areas: the illicit cultivation; illicit demand; 
illicit production, trafficking and use of internationally controlled 
substances; the diversion of precursors; and money laundering (p. 
14).2 The two-day ministerial segment, added to the regular CND 
session, was convened to take stock of the implementation of 
the commitments made in that declaration. It included a general 
debate as well as two interactive, multi-stakeholder round table 
meetings that were conducted in parallel. One focused on the 
question of taking stock of implementation, by analysing existing 
and emerging trends, gaps, and challenges. The other focused 
on strengthening international cooperation, including means of 
implementation, capacity-building, and technical assistance, on 
the basis of common and shared responsibility.
A ministerial declaration was agreed as part of the segment, 
‘strengthening our actions at the national, regional and 
international levels to accelerate the implementation of our 
joint commitments to address and counter the world drug 
problem’.3 It is beyond the scope of this article to detail the wide 
variety of commitments made in the declaration but, broadly 
speaking, it does not represent any fundamental change in UN 
drug policy from that which has emerged over the last decade. 
It makes an ongoing commitment to achieving the ‘operational 
recommendations and aspirational goals’3 set out in the 2009 
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6 International Drug Policy Consortium (IDPC) (2019) The ‘Vienna 
consensus’ stifles progress on UN drug policy: Statement from the 
International Drug Policy Consortium. London: IDPC. 
Available online at:      
http://fileserver.idpc.net/library/Public-IDPC-statement_FINAL.pdf
7 Eurasian Harm Reduction Association (EHRA) (2019) Not learned 
lessons: 10 more years to be left behind. Vilnius: EHRA. Available 
online at:      
https://harmreductioneurasia.org/not-learned-lessons-10-more-
years-to-be-left-behind/
International 
guidelines on human 
rights and drug policy
The United Nations Development Programme (UNDP); the Joint 
United Nations Programme on HIV/AIDS (UNAIDS); the World 
Health Organization; and the International Centre on Human 
Rights and Drug Policy have collaborated with international 
experts to produce International guidelines on human rights and 
drug policy.1 The outputs of this collaboration were launched to 
coincide with the 62nd session of the Commission on Narcotic 
Drugs (CND) in March 2019 – they include a written set of 
guidelines and an online resource.2
Context
Human rights increasingly feature within international drug policy 
outputs. For example, every major UN political declaration on 
drug control since the late 1990s has reaffirmed the UN General 
Assembly resolutions’ acknowledgement that ‘countering the 
world drug problem’ must be carried out ‘in full conformity’ with 
‘all human rights and fundamental freedoms’.3 However, while 
their importance has been recognised in writing, this has not 
always been reflected in practice internationally. The authors 
argue that one of the barriers to adopting a more human rights-
based approach is a lack of clarity as to what human rights law 
requires of states in the context of drug control law, policy, and 
practice. The guidelines set out to address that gap.
Guidelines
The guidelines do not create new rights but highlight what 
states should and should not do to develop human-rights-
compliant drug policies – meeting their human rights obligations, 
while also complying with their obligations under the various 
international drug control conventions.4 They are grounded in 
the international evidence base and aim to guide stakeholders 
involved in policymaking across the spectrum of related activities 
from cultivation to consumption. In doing so, the document 
covers a range of policy areas, from development to criminal 
justice to public health. It is important to note that this is not 
a toolkit for how to do drug policy, instead the guidelines are 
described as a ‘reference tool’ for stakeholders who are working 
at local, national, and international levels to ensure human rights 
compliance.
The guidelines are structured around five sections, as laid out in 
their introduction (pp. 4–5):
Section I presents general cross-cutting, or 
‘foundational’, human rights principles underpinning 
the Guidelines, which may be seen as applicable 
irrespective of the issue or specific right in question.
Section II sets out universal human rights standards 
in the context of drug policy, taking the rights in 
question as its starting point. The section includes a 
brief overview of each human rights standard and its 
relation to drug policy before identifying consequent 
State obligations and recommended measures for 
human rights compliance. It should be noted that the 
order of this section does not imply any hierarchy of 
rights. It begins with the right to health to reflect the 
health goal of the international drug control system.
Section III addresses human rights concerns arising out 
of drug policy as it affects a number of specific groups: 
children, women, persons deprived of their liberty, and 
indigenous peoples. These, of course, are not the only 
groups with specific human rights needs or concerns 
of relevance to drug policy. They are emphasised as 
a consequence of more developed law concerning 
their specific human rights in relation to drug policy. 
Many others also experience disproportionate harm, 
inequities, and intersecting forms of discrimination on 
grounds of race, ethnicity, nationality, migration status, 
disability, gender identity, sexual orientation, economic 
status, and the nature and location of livelihood, 
including employment as rural workers or sex workers. 
The universal rights described in these Guidelines 
apply equally to these individuals and groups.
Sections IV and V conclude by outlining general matters 
related to the implementation of human rights obligations 
and relevant principles of treaty interpretation.
The Guidelines have been designed to place human 
rights at the forefront. However, many readers may 
approach the Guidelines with a focus on a specific 
drug policy topic or theme, or may be unfamiliar with 
specific rights. To assist with navigating the Guidelines, 
Annex I provides three thematic reference guides 
for development, criminal justice, and health. Each 
thematic guide brings together the most relevant 
guidelines for each of these issue areas.
An interactive website is also available to stakeholders. It contains 
extensive commentaries and references that complement the 
guidelines document. Stakeholders can search by specific rights, 
drug control themes, and other keywords, as well as follow links 
to source material.2
Lucy Dillon
1 United Nations Development Programme (UNDP) (2019) 
International guidelines on human rights and drug policy. New York: 
UNDP. https://www.drugsandalcohol.ie/30447/
2 For the guidelines and online resource, visit:   
https://www.humanrights-drugpolicy.org/
Commission on Narcotic Drugs  
continued
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Human rights and drug policy  
continued
3 See, for example, the UN General Assembly, Resolution 73/192: 
International cooperation to address and counter the world drug 
problem, UN Doc. A/RES/73/192 (2019). Available online at:  
https://www.un.org/en/ga/search/view_doc.asp?symbol=A/
RES/73/192
4 Single Convention on Narcotic Drugs (as amended by the 1972 
Protocol) 520 UNTS 7515 (1961); Convention on Psychotropic 
Substances, 1019 UNTS 14956 (1971); Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances, 1582 UNTS 95 
(1988). Available online at: https://treaties.un.org/
UNAIDS report on 
health, rights and 
drugs
A Joint United Nations Programme on HIV/AIDS (UNAIDS) report, 
Health, rights and drugs: harm reduction, decriminalization and 
zero discrimination for people who use drugs, was published in 
March 2019.1 It recommends implementing evidence-informed 
approaches to drug policy that are grounded in human rights 
and which would reduce the spread of HIV and other diseases 
through injecting drug use. These include harm reduction 
services and the decriminalisation of the possession of drugs 
for personal use. The report was published in advance of 
the ministerial segment of the 62nd Commission on Narcotic 
Drugs (CND) session and its authors advocated that its 
recommendations be used to inform that process.2
UNAIDS
UNAIDS was established in 1996 and describes itself as ‘leading 
the global effort to end AIDS as a public health threat by 2030 
as part of the Sustainable Development Goals’.3 It is at the 
core of the design, delivery, and monitoring of the global AIDS 
response, including shaping public policy on HIV. As part of its 
work, it leads on global data collection on HIV epidemiology, 
programme coverage, and finance. As a structure, UNAIDS is 
different from other elements of the UN system in that it is the 
only co-sponsored joint programme – it draws on the experience 
and expertise of 11 UN system co-sponsors, including the United 
Nations Office on Drugs and Crime (UNODC). It is also the only 
UN entity with civil society represented on its governing body. 
This more inclusive structure appears to contribute to UNAIDS’ 
position as an advocate for a human rights and public health led 
approach to drug policy.
Health, rights and drugs
Health, rights and drugs shows that people who use drugs 
are being left behind when it comes to ongoing HIV infection. 
Despite a 25% decline in the incidence of HIV infections globally 
(all ages) between 2010 and 2017, HIV incidence is not declining 
among people who inject drugs. The report argues that this 
reflects a failure on the part of policymakers and lawmakers 
internationally to protect the health and human rights of drug 
users. Users continue to be unable to access interventions that 
have been evidenced to reduce the risk of infection – harm 
reduction interventions such as needle exchanges and opioid 
substitution therapy. In the foreword to the report, the executive 
director of UNAIDS, Michel Sidibé, describes this situation as 
‘unacceptable: people who use drugs have rights, and too often 
these rights are being denied’ (p. 1).
The report has four substantive chapters. The first presents 
the current global situation in which drug users tend to be 
criminalised and are heavily stigmatised. This contributes 
to a situation in which they are more vulnerable than other 
members of the population to drug-related infectious diseases; 
experience heightened levels of violence; and have higher rates 
of mortality. The second chapter argues that harm reduction is 
the foundation of a rights-based public health approach, and 
shows how it has consistently been found to reduce morbidity 
and mortality among people who use drugs.
Chapter 3 highlights the contradiction in current international 
drug policy. It is noted that the dominant approach continues to 
be one of criminalisation ‘despite countries agreeing again and 
again … that drug policy must be informed by human rights and 
committing to adopting a more balanced, integrated, evidence-
informed and human rights-based approach’ (p. 33). The fourth 
chapter explores the role of civil society in promoting rights and 
health-based approaches to drug use, bringing about changes in 
attitudes and policies, and delivering harm reduction services.
Conclusion
The authors conclude that by taking an approach characterised 
by criminalisation and law enforcement, the global drug 
framework has failed to achieve the global target to ‘eliminate 
or reduce significantly and measurably’ (p. 45) the supply and 
demand for illicit drugs by 2019. Instead, the situation has 
worsened. They argue for comprehensive harm reduction 
services and the decriminalisation of drug use and possession for 
personal use (see Box 1).4
UNAIDS recommendations
In the report, UNAIDS outlines a set of recommendations4 for 
countries to adopt, which include:
1 Fully implementing comprehensive harm reduction and 
HIV services, including needle–syringe programmes, opioid 
substitution therapy, overdose management with naloxone, 
and safe consumption rooms.
2 Ensuring that all people who use drugs have access to 
prevention, testing, and life-saving treatment for HIV, 
tuberculosis, viral hepatitis, and sexually transmitted 
infections.
3 Decriminalising drug use and possession for personal use. 
Where drugs remain illegal, countries should adapt and 
reform laws to ensure that people who use drugs have 
access to justice, including legal services, and do not face 
punitive or coercive sanctions for personal use.
4 Taking action to eliminate all forms of stigma and 
discrimination experienced by people who use drugs.
5 Supporting the full engagement of civil society as a source 
of information and to provide community-led services, 
mobilisation, and advocacy, especially in places where 
repressive policies and practices are the norm.
6 Investing in human rights programmes and health services, 
including a comprehensive package of harm reduction 
and HIV services, community-led responses, and social 
enablers.
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Lucy Dillon
1 Joint United Nations Programme on HIV/AIDS (UNAIDS) (2019) 
Health, rights and drugs: harm reduction, decriminalization and 
zero discrimination for people who use drugs. Geneva: UNAIDS. 
https://www.drugsandalcohol.ie/30409/
2 See accompanying article of this Drugnet issue: Dillon L (2019) 
Ministerial segment of 62nd session of Commission on Narcotic 
Drugs. Drugnet Ireland, 70: 5–6.
3 UNAIDS (2018) About UNAIDS: Saving lives, leaving no one behind. 
Geneva: UNAIDS. Available online at:    
http://www.unaids.org/en/whoweare/about
4 UNAIDS (2019) Press release: Promises to improve health 
outcomes for people who inject drugs remain unfulfilled as 
99% do not have adequate access to harm reduction services. 
Geneva: UNAIDS. Available online at:    
http://www.unaids.org/en/resources/presscentre/
pressreleaseandstatementarchive/2019/march/20190313_drugs_
report
European drug 
trends, 2019
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) published the European drug report 2019: trends and 
developments1 on 6 June 2019. This report provides a snapshot 
of the latest drug trends across the 28 European Union (EU) 
member states, Norway and Turkey. The Health Research Board 
(HRB) provides the Irish data.
Europe is seeing signs of an increase in cocaine availability, with 
seizures at record levels. The report shows that in the EU 28, 
Norway and Turkey over one million seizures of illicit drugs are 
reported annually, around 96 million adults aged 15–64 years 
have tried an illicit drug in their lifetime, and 1.2 million people 
receive treatment each year for illicit drug use. In 2018, some 55 
new psychoactive substances (NPS) were detected in Europe for 
the first time, bringing the total monitored by the EMCDDA to 
730.
Commenting on the report, the Minister of State with 
responsibility for the National Drugs Strategy, Catherine Byrne 
TD, said:
The drug problem across Europe and here at home 
is of great concern, and the growing problem of 
cocaine use is particularly worrying. In response, the 
HSE has developed a campaign to raise awareness 
of the dangers associated with cocaine and crack 
cocaine use. I have also recently allocated funding 
for the development of strategic health initiatives by 
the HSE and Drug and Alcohol Task Forces around 
the country, and it is anticipated they will include 
projects to tackle cocaine use.
The report also highlights the issue of drug 
poisonings. Any death from drug use is a tragedy 
and we must continue to promote harm reduction 
and prevent overdose. Across Europe, Supervised 
Injecting Facilities have been instrumental in reducing 
drug-related harm and I remain firmly committed 
to the establishment of a pilot facility in Dublin 
city. I also welcome the increase in the provision of 
Naloxone and training in its delivery as another public 
health measure which can greatly reduce overdose 
deaths in Ireland.2
Cocaine seizures, distribution and health issues
Cocaine seizures are at the highest level for many years and 
the drug is becoming increasingly available. Around 73,000 
people entered treatment for cocaine-related problems in 2017, 
with worrying numbers involved in crack cocaine use, which is 
evident in Ireland as well. The price of cocaine has not increased 
but in 2017 the purity of the drugs at street level reached the 
highest it had been for a decade. While large-volume trafficking 
is still a major challenge for law enforcement agencies, there is 
increasing evidence that distributors are taking advantage of the 
opportunity presented by social media, the darknet, and other 
technological advances.
Heroin is still the most common illicit opioid on the drug market 
in Europe and is a major contributor to health and social costs. 
Seizures of heroin and of acetic anhydride, a precursor chemical, 
have increased as have discoveries of heroin-processing 
laboratories. The synthetic opioids that have driven the opioid 
epidemic in North America only represent a small share of the 
European drug market but they are a growing concern with links 
to overdoses and death. Six fentanyl derivatives were detected 
in Europe for the first time in 2018. Drug treatment monitoring 
data indicate that one in every five clients entering treatment for 
opioid use now reports a synthetic opioid as their main problem 
drug.
Cannabis remains the most widely used illicit drug in Europe. 
Some 17.5 million or 14.4% of young Europeans (15–34 years) are 
estimated to have used cannabis in the last year (EU-28). Around 
1% of adults (15–64 years) in the EU are estimated to be daily, or 
almost daily, cannabis users. Cannabis is now the substance most 
often named by new entrants to drug treatment as their main 
reason for contact.
Synthetic drug production in Europe appears to be growing, 
diversifying, and becoming more innovative. Europe is producing 
amphetamines and MDMA for use in Europe and globally. The 
purity of both types of drugs is as high as it has been for several 
years and there are indications of increasing levels of production, 
such as raids on MDMA laboratories and detections of precursor 
dumping.
The situation described in the European drug report is 
presented below under a series of headings. The EMCDDA used 
the most recent data available to provide aggregate figures. 
While data on some indicators, such as treatment demand, are 
supplied annually, the year of the most recent prevalence data 
can vary.
UNAIDS report on health, rights 
and drugs  continued
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Cocaine
European situation
• Around 2.6 million young adults (15–34 years) have used 
cocaine in the last year across Europe. Of the 12 countries 
that have reported prevalence figures since 2016, three 
have reported higher estimates and nine countries were 
stable compared with the previous survey.
• Between 2014 and 2017, there was a 35% increase in the 
number of first-time entrants to drug treatment services 
with cocaine as a main problem drug.
• An estimated 10,600 clients entered treatment for primary 
crack cocaine use in 2016. Many of these clients report 
heroin as a secondary problem drug and they tend to be 
more socially marginalised than those in treatment for the 
use of powder cocaine.
• Analyses of municipal wastewater demonstrated an 
increase in cocaine residues in 22 cities (out of a total of 38) 
between 2017 and 2018.
Cannabis: availability and use
• Cannabis is the most commonly used illicit drug in Europe, 
across all age groups.
• The EMCDDA estimates that 14.4% of young adults (15–34 
years) – an estimated 17.5 million people – used cannabis in 
the last year. Last-year prevalence in this age group ranged 
from 3.5% in Hungary to 21.8% in France.
• Cannabis is responsible for the greatest share of new 
entrants to treatment. The overall number of people 
entering treatment for the first time and who are seeking 
treatment for problem cannabis use increased by 67% 
between 2006 and 2017, although there was a small reverse 
between 2016 and 2017.
• In 2017, there were 782,000 seizures of cannabis products 
reported in the EU.
New psychoactive substances
• Data on NPS are based on notifications by member states 
to the EU Early Warning System (EWS). In 2018, some 55 new 
substances were reported for the first time (51 in 2017). By 
the end of 2018, the EMCDDA was monitoring more than 
730 NPS, compared with around 300 monitored in 2013. 
The number of new substances being identified for the ﬁrst 
time each year increased sharply between 2009, when 24 
were identified, and 2014, when there were 101 notifications, 
but has since declined with 55 identified in 2018.
• 390 substances, approximately one-half of the new 
substances being monitored by the EU EWS, were detected 
in Europe in 2017.
• In 2017, almost 78,000 seizures of NPS were reported across 
Europe, 53,000 of which were in EU member states.
• Synthetic cannabinoids and cathinones were the most 
frequently seized NPS in 2017, with just over 32,000 seizures 
reported. In total, 118 synthetic cathinones have been 
identified since 2005, with 14 reported for the first time in 
2016, a decrease from the 31 reported in 2014.
• Production of MDMA is concentrated in Belgium and 
the Netherlands and has increased in recent years as 
substitutes for controlled precursors of the drug have 
become more available.
• An estimated 6.6 million MDMA tablets were reported 
seized in 2017, the highest number reported in the EU in any 
year since 2007.
• The EMCDDA estimates that 2.1 million young adults (15–34 
years), or 1.7% of this age group, used MDMA/ecstasy in 
the last year. National estimates vary considerably with the 
Netherlands highest at 7.1%.
Opioids (mainly heroin)
• There were an estimated 1.3 million high-risk opioid users in 
Europe in 2017.
• In 2017, use of opioids was reported as the main reason 
for entering specialised drug treatment by 177,000 clients 
or 37% of all those entering drug treatment in Europe. Of 
these, 32,000 were first-time entrants, a drop of 3,800 
compared with the previous year. The number of first-time 
heroin clients more than halved from a peak in 2007, to a 
low point in 2013.
• It is estimated that at least 8,279 overdose deaths, mainly 
involving opioids, occurred in the EU in 2017. As in previous 
years, the United Kingdom (34%) and Germany (13%) 
together account for nearly one-half of the European total.
Brian Galvin
1 European Monitoring Centre for Drugs and Drug Addiction (2019) 
European drug report 2019: trends and developments. Luxembourg: 
Publications Office of the European Union.   
https://www.drugsandalcohol.ie/30619/
2 Health Research Board (HRB) (2019) HRB compares Irish drug 
situation with the rest of Europe. Dublin: HRB.   
https://www.hrb.ie/news/press-releases/single-press-release/
article/hrb-compares-irish-drug-situation-with-the-rest-of-
europe/
At the launch of the 
European drug report 
2019 in June, European 
Commissioner for 
Migration, Home Affairs 
and Citizenship, Dimitris 
Avramopoulos, and 
EMCDDA Director Alexis 
Goosdeel (left)
European drug trends, 2019  
continued
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9 Alcohol industry 
involvement in 
policymaking: a 
systematic review
Research indicates that the most eff ective alcohol policies 
are those that regulate the actions of the alcohol industry, 
including reducing the aff ordability of alcohol and decreasing 
its availability.1 However, national alcohol policies have tended 
to favour policies that allow the alcohol industry scope for 
self-regulation and promote non-regulatory measures. 
This may refl ect the infl uence of the alcohol industry in 
defi ning the scope and content of alcohol policy debate. A 
recent systematic review2 published in the journal Addiction 
investigated the role of the alcohol industry in policymaking 
and the ways in which the industry attempts to infl uence this 
process.
Methods
The authors searched for peer-reviewed studies published 
between 1980 and 2016. A total of 15 unique studies published 
in 20 articles were included in the review. The majority of these 
studies were carried out in high-income, English-speaking 
countries, including the United Kingdom, the United States, 
Australia, and New Zealand. The remaining studies were carried 
out in Africa, Thailand, Hong Kong, and Poland. The studies 
were primarily qualitative and a thematic approach was used to 
synthesise the fi ndings.
Main fi ndings
The authors found that the alcohol industry had a ‘pervasive 
infl uence’ on policymaking across all countries and all policy 
contexts. They identifi ed two ways in which the alcohol industry 
sought to infl uence policy. The fi rst was framing the policy 
debates in a clear and convincing manner that was protective 
of commercial interests. The second was infl uencing policy 
activities to manage potential threats to industry interests 
through the use of short-term and long-term lobbying 
strategies.
1. Framing the debate
Strategically, alcohol industry actors placed themselves as key 
partners to the government in developing and implementing 
alcohol policy. This legitimised their position at the table, giving 
them scope to shape the content and nature of the policy 
debate. They used this position to steer policy discussion away 
from policies that would restrict the industry’s ability to price, 
advertise, and brand their products.
Industry actors attempted to shift the responsibility of alcohol 
consumption and related harms away from alcohol and the 
alcohol industry and towards the individual consumer. This 
allowed them to advocate for a policy response that would 
target a minority of heavy alcohol users. Industry actors were 
found to advocate for ‘partnership’ approaches, such as 
industry-led education and targeting smaller subpopulations 
of high-risk drinkers. The authors reported that industry actors 
were found to use misleading claims about the eff ectiveness of 
their proposed interventions and to question the unintended 
consequences of population-based strategies as well as its 
evidence base. In this way, alcohol industry actors can be seen 
to be making strong rhetorical commitments to evidence-
based policy while protecting their own commercial interests.
2. Infl uencing activities
Across all of the studies, alcohol industry representatives 
sought to be involved in every aspect of the policymaking 
process, including public consultations, parliamentary 
committees, and working groups. They engaged in both short-
term and long-term lobbying tactics. Long-term lobbying 
strategies included sustained eff orts to build close and 
lasting relationships with key policymakers through frequent 
contact and other forms of engagement. This normalises the 
involvement of industry actors in policy processes, helps keep 
any issues that would be contrary to commercial interests off  
policy agenda, and provides a basis for reactive lobbying in 
response to specifi c policy debates or issues that may arise. 
Alcohol industry actors were also found to use third parties 
from outside the industry to engage policymakers. This includes 
funding think tanks or academics to carry out or disseminate 
policy-relevant research with supportive fi ndings, creating a 
separate body of literature that could be referenced to support 
their policy positions.
Conclusions
This systematic review demonstrates that alcohol industry 
actors are strategically involved in policymaking to advance 
their own commercial interests. The authors note that industry 
actors can make ‘intuitively plausible, and highly nuanced, 
arguments that can appear compelling if they are allowed to go 
unchallenged’ (p. 1574).2
Claire O’Dwyer
1 Babor TF, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham 
K, et al. (2010) Alcohol: no ordinary commodity – research and 
public policy. Oxford: Oxford University Press.
2 McCambridge J, Mialon M and Hawkins B (2018) Alcohol industry 
involvement in policymaking: a systematic review. Addiction, 113(9): 
1571–84. https://www.drugsandalcohol.ie/30180/ 
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Community 
experiences of 
serious organised 
crime in Scotland
In June 2018, a report that examined community experiences 
of serious organised crime (SOC) in Scotland was published by 
the Scottish Government.1 The study aimed to examine three 
areas:
• Relationships that existed between SOC and communities 
in Scotland
• Experiences and perceptions of the scope and nature of 
SOC among residents, stakeholders, and organisations
• Impact of SOC on community wellbeing, and whether 
harms linked to SOC can be alleviated.
Methodology
This study drew on a qualitative approach and involved four 
stages. Overall, data were collected from 188 participants.
Stage 1: Site selection
The site selection was based on community experiences of 
organised crime, interviews with key stakeholders (e.g. police, 
statutory and voluntary agencies), police intelligence, and 
analyses by the Scottish Community Development Centre.
Stage 2: Case study fieldwork
Qualitative interviews, focus groups and observations were 
carried out between February and November 2017, with 
community participants and agencies using two research 
teams. This was to minimise harm and to ensure anonymity 
and confidentiality. The themes addressed in the interviews 
included perceptions of community; meanings associated with 
‘organised’ crime; experiences of victimisation and/or crime; 
and changes over time (p. 19). A thematic interview template 
was utilised in interviews. Questions were modified according to 
respondents, experiences, and community. Young people (n=16) 
and teachers (n=2) from three secondary schools took part in 
focus groups (n=5). Table 1 shows the demographic profile of 
the community participants.
Informal interviews and observations were carried out in 
local business premises (n=12). These interviews explored 
the advantages and disadvantages of doing business in these 
areas; security; victimisation; relationships; and perceptions 
of organised crime. To ensure anonymity, no demographic 
details were recorded. Interviews with key stakeholders (n=52) 
explored the nature and patterns of organised crime, changes 
over time, interventions, and success and failures (p. 20).
Stage 3: Triangulation
A data calibration exercise detected two gaps in the data 
collection. Hence, two more data-collections were carried out:
1 Interviews and focus groups were carried out with 
individuals with a lived experience of organised crime 
(n=12).
2 Interviews were carried out with community and statutory 
agencies who were engaged in crime of a more diffuse 
nature (n=14, p. 21).
Stage 4: Data analysis and community co-inquiry
Following data analysis, the findings were presented to a 
subsample of participants (n=33) at ‘co-inquiry events’ (p. 
22). These events involved a two-stage process. Participants 
were first asked to discuss whether the findings were or were 
not in alignment with their experiences. Then they were 
asked to consider changes in practice, policy or community 
responses that could stop crime, address social determinants, 
and address the impact of crime in the community. The 
outcomes of this process informed final conclusions and 
recommendations.
Results
The main findings were categorised into four themes: 
community experiences; narratives; emergent and diffuse 
organised crime; and service delivery and community response.
Community experiences
Organised crime was identified as a prevailing and routine 
aspect of normal everyday living in local communities. It was 
believed that firms, families and ‘faces’ involved were ‘local’ (p. 
3).2 The most prominent crime visible was street crime, such as 
drug dealing and theft. However, it was acknowledged that most 
SOC crimes were not visible to the public. The main impact of 
SOC in Scotland was believed to be the result of the illicit drugs 
market, which results in harmful outcomes for users, their 
families, and community as a whole.
Table 1: Demographic profile of community participants
Field site Male Female <18 yrs 18–30 yrs 31–50 yrs 51–75 yrs Total
Site 1 10 14 2 4 13 5 24
Site 2 10 11 9 4 4 4 21
Site 3 10 14 5 3 10 6 24
Site 4* 3 12 0 4 10 1 15
Totals 33 51 16 15 37 16 84
Source: Frazer et al., 2018, p. 20
* Site 4 involved fieldwork in two ‘mini’ case study sites.
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serious organised crime in 
Scotland continued
Narratives
A range of narratives emerged across case study sites relating 
to the push and pull factors that led to organised crime 
involvement, such as:
• Poverty and inequality
• Family, mentoring and recruitment
• Boredom and excitement
• ‘Flash cars’ and ready cash.
Emergent and diffuse organised crime
While it was evident that the nature, form, and extent of SOC 
today was similar to previous generations, there was evidence 
to suggest that new trends were emerging in relation to youth 
crime, drug distribution, and market diversification (p. 45). 
Advancements in technology played a part. For example, it was 
no longer vital to be part of a gang, recruitment could easily 
occur via social media as and when needed. Mobile flexible 
markets have become common in smaller locations where a 
SOC presence was not evident; they operated differently to 
those elsewhere. For example, mobile criminal actors were 
known to take over premises by taking advantage of people 
with vulnerabilities, such as age, addiction, or mental health 
(p. 48). Occasionally, these mobile networks worked with 
local crime groups and were known to collaborate on other 
criminal offences (p. 49). The ability for SOC offenders to set up 
legitimate businesses in order to launder and invest money was 
viewed as a real threat to the community. No links were shown 
between organised crime groups and migrant communities; 
however, similar to other vulnerable cohorts, there was some 
evidence to suggest that they were vulnerable to labour 
exploitation and human trafficking.
Service delivery and community response
The presence of SOCs was considered a challenge for services 
and its delivery. By their very nature, extensive resources 
are required to address the problems that arise along with 
their associated effects on the community. In addition, other 
obstacles, such as stigma, fear and mistrust, existed between 
communities and services as well as reduced responses by 
service providers to poverty and social exclusion. Existing levels 
of austerity further exacerbated these issues.
Conclusion and recommendations
Recommendations were put forward to address the four main 
themes that emerged in the course of the study:
• Developing resilient communities: The existing SOC 
strategy, framed by four strategic principles – Divert, 
Deter, Detect and Disrupt – should be extended to include 
an additional D – Develop, which should be aimed at 
addressing harms connected to organised crime.
• Changing the narrative: Narratives should be challenged at 
a national, community, and individual level.
• Addressing vulnerability: Strategies are required to prevent 
the exploitation of individuals that are vulnerable.
• Broadening community partnership: In order to develop 
cohesive interventions and responses, it is important that 
police, community, and statutory organisations work in 
partnership.
This is the first study to investigate community experiences of 
SOC in Scotland. It has extended knowledge and understanding 
of organised crime within Scottish communities in locations 
where SOC is embedded and where mobile forms of SOCs are 
present. As acknowledged by the authors, ‘only by shining a 
light on an issue that is often in the shadows, or is disordered 
through the glare of media glamourisation and dubious forms 
of celebrity, can real and effective responses be formulated’ (p. 
79).
Ciara H Guiney
1 Fraser A, Hamilton-Smith N, Clark A, Atkinson C, Graham W, 
McBride M, et al. (2018) Community experiences of serious 
organised crime in Scotland: research report. Edinburgh: Scottish 
Government. Available online at:    
https://www.gov.scot/publications/community-experiences-
serious-organised-crime-scotland/
2 Scottish Government (2018) Community experiences of serious 
organised crime in Scotland: research findings. Edinburgh: Scottish 
Government. Available online at:    
https://www.gov.scot/publications/community-experiences-
serious-organised-crime-scotland-research-findings/
The drug economy 
and youth 
interventions
The launch of The drug economy and youth interventions: 
an exploratory research project on working with young 
people involved in the illegal drugs trade was held on 30 April 
2019.1 The study was carried out by Dr Matt Bowden of the 
Technological University Dublin and is published by CityWide 
Drugs Crisis Campaign. As well as a presentation on the report’s 
key findings, the launch included:
• The findings of research into the views and experiences of 
drug dealers by Dr Fiona O’Reilly
• The experiences of those delivering interventions with 
young people affected by the ‘drug economy’:
  –  Angela Birch of the Ballymun Regional Youth Resource  
 discussing the Easy Street project
  –  Karl Ducque and Gary Lawlor of the Targeted Response  
 to Youth (TRY) intervention
• A closing statement by John Lonergan, former governor of 
Mountjoy Prison, Dublin.
Drug economy and youth interventions
The drug economy and youth interventions report stems from 
a 2016 study on drug-related intimidation that identified a need 
to explore the issue of early intervention with young people 
involved in drug distribution in Ireland.2 The report presents the 
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interventions continued
findings of an exploratory study based on a review of the Irish 
and international literature on violence and intimidation in the 
illegal drug trade and in-depth qualitative interviews with seven 
practitioners working in the Dublin area.
Literature review
The literature review depicts an environment in which Irish 
drug markets have become more complex over the last couple 
of decades. There are a number of reasons given for this 
growing complexity, including the changing profile of drug use 
to polydrug use; the open nature of dealing and use in public 
places; the debt-based nature of distribution; and a greater 
association of the market with violence and intimidation. A 
working definition of intimidation cited in the report ‘is “a 
serious, insidious and coercive behaviour intended to force 
compliance of another person against their will” … involving 
verbal threats or actual physical violence’ (p. 10).
Experiences of working with young people
The main body of the report presents the findings of the 
qualitative work. Those interviewed had all worked with young 
people and families in the community who had experienced 
drug-related problems, were involved in some form of drug 
selling or holding, and had experienced some associated 
violence or threat of violence. They varied in their level of 
experience (from seven to 35 years of working in the field) 
and were based in different kinds of projects – youth work, 
drug teams, social work, and youth diversion. Their narratives 
explored the context in which they were delivering their 
services, the nature of the problem faced by young people 
with whom they worked, and possible ways of addressing these 
challenges.
Key findings
Key findings are outlined below.
Nature of the problem
• The drug economy provides opportunities for young 
people to access work; the structure of drug distribution 
networks provides a range of roles from various levels of 
dealers to those who ‘hold’ or ‘carry’ drugs. Working within 
this economic structure enables young people to access 
cash and consumer goods. This, it was argued, provides 
a more attractive alternative to ‘precarious’ labour in, for 
example, the service industry: ‘Drug selling is regarded 
as an alternative to labour market participation: seen as 
a type of entrepreneurship in an unregulated economy’ 
(p. 17). Economic terms were often used by participants 
when describing the system of distribution – labour force 
participation, qualifications, skills, etc.
• Drug distribution is based on a financial system of credit 
or ‘fronting’ – recouping of debts operates under the 
threat of violence. Drug-related intimidation and drug 
debt intimidation are described as central to how these 
distribution networks are structured and feed into an 
environment where ‘dominant drug dealers appear to rule 
within communities’ (p. 30).
• In an environment where drug use was described as 
‘normalised’ and distribution structured around peer-
to-peer networks, initiation into the drug economy was 
found to go unrecognised at times. The term ‘grooming’ 
was used by some participants to describe the process 
whereby a young person starts to do favours for those 
involved in distribution in return for small amounts of cash. 
As they show they can be trusted, they can then progress to 
holding money, drugs or weapons. While this is sometimes 
in exchange for cash, movement into these more involved 
roles in the distribution network can be required as a way 
of paying a drug debt.
• While intimidation was predominantly a male experience, 
females were far from immune. The author identifies a 
particular concern about young women being asked to 
engage in sexual activity to expunge debts.
How to tackle the problem
• Based on the participants’ experiences of working with 
young people in the community, a gap was identified in 
current drug education and prevention practice. It was 
suggested that there should be an increased focus on 
educating young people about the nature of the drug 
economy and how it uses credit and debt as an economic 
bond that often leads to intimidation and violence. This was 
key where drug distribution is peer-to-peer – young people 
need to understand that drugs are not free, by accepting 
them without immediate payment, they are entering an 
economic bond that will require payment of some kind.
• A recurring theme was that young people involved in drug 
distribution are not ‘untouchable’. Service providers have 
found ways to engage with these young people and help 
them desist from their role in the drug economy. Central 
to this is the quality of the relationship that a worker has 
with the young person. Where this is based on a common 
understanding and respect, it is possible to have a positive 
impact on the young person’s decision-making and to 
support a desistance process.
• In a context where the drug economy offers young people 
access to income, there was a call for access to ‘real’ 
or ‘proper’ educational and work pathways to be made 
available as an alternative.
• The report argues that young people who live in the 
areas where a drug economy exists need to have more 
of a voice in the narrative that defines their realities. The 
‘gangland’ narrative predominates in the media, which is 
unhelpful when trying to find solutions to the problems 
being experienced by young people in these areas. It also 
contributes to the stigmatisation of young people from 
certain areas, irrespective of any involvement in the drug 
economy.
• There was a call for improved early intervention through 
child and family preventive services, as a way of addressing 
intergenerational poverty.
• For policing and criminal justice responses, participants 
identified a need for authorities to be able to target the 
assets of those involved in the drug economy using ‘a model 
similar to the Criminal Assets Bureau, except working on a 
micro level’ (p. 28); and to introduce some way of measuring 
social harm and applying it within the criminal justice 
responses.
Easy Street and Targeted Response to Youth
At the launch of the report, there were presentations from 
two projects that work to support young people involved in 
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or at risk of becoming involved in the drug economy – Easy 
Street project in Ballymun, Dublin3 (running since 2009) and the 
Targeted Response to Youth (TRY) on Donore Avenue, Dublin4 
(first piloted in March 2017). The evidence-based approach 
taken in these projects is identified in the report as a suitable 
model for working with young people. Broadly speaking, both 
projects take an outreach and bridging approach, in which 
youth workers make contact at street level, build trust, and 
then act as a ‘connecting node’ or ‘host’ to enable young 
people to extend their social networks beyond those associated 
with the drugs economy and to build on positive traits. They 
work with individual young people and broader networks 
of young people in the community. They also support them 
in accessing education or work pathways, with the aim of 
either preventing them engaging in or desisting from the drug 
economy. While neither project has carried out an outcome 
study, both described positive experiences of working with 
young people within this model. Particular challenges they 
faced were in securing adequate funding to meet the level of 
demand for their work and having access to viable education 
and employment opportunities for their young people.
Concluding comment
There were three recurring themes throughout the 
presentations and the subsequent discussion. First, people 
were conflicted about engaging with people who were 
involved in drug distribution in their communities. However, 
it was explained that doing so was about understanding their 
behaviour with the aim of prevention; it was not about excusing 
their behaviour. The second recurring theme for practitioners, 
including John Lonergan, former governor of Mountjoy Prison, 
was the need for any engagement to be structured around a 
strong relationship with an advocate, characterised by trust 
and understanding. Third was the message that young people 
involved in the drug economy or at risk of getting involved 
were reachable. If there were to be viable educational and 
employment pathways open to them, it was believed that many 
would desist from the drug economy.
Lucy Dillon
1 Bowden M (2019) The drug economy and youth interventions: 
an exploratory research project on working with young people 
involved in the illegal drugs trade. Dublin: CityWide Drugs Crisis 
Campaign. https://www.drugsandalcohol.ie/30487/
2 Connolly J and Buckley L (2016) Demanding money with menace: 
drug-related intimidation and community violence in Ireland. 
Dublin: Citywide Drugs Crisis Campaign.   
https://www.drugsandalcohol.ie/25201/
3 For further information on the Easy Street project, contact Angie 
Birch of Ballymun Regional Youth Reach Resource on 
angie.birch@bryr.ie and http://www.bryr.ie/
4 For further information on the TRY project, contact Fearghal 
Connolly, project coordinator, Donore Community Drug and 
Alcohol Team on fearghal@donorecdat.ie and 
https://www.donorecdat.ie/
Alcohol treatment 
figures from the 
NDTRS, 2011–2017
The National Drug Treatment Reporting System (NDTRS) is a 
national surveillance database on treatment for problem drug 
and alcohol use in Ireland. In March 2019, the NDTRS published 
its latest alcohol treatment figures, which cover the seven-year 
period 2011–2017. Over this period, 55,675 cases were treated 
for alcohol as a main problem.1 
Key findings
The number of cases decreased to 7,350 in 2017 from a high 
of 8,876 in 2011. The proportion of new cases treated (those 
never before treated for problem alcohol use) decreased from 
52.3% in 2011 to 47.6% in 2017 (see Table 1). The proportion of 
previously treated cases increased over the reporting period 
from 46.3% in 2011 to 49.7% in 2017.
It is important to note that each case in the NDTRS database 
relates to a treatment episode and not to a person. This 
means that the same person may be counted more than once 
in the same calendar year, if that person had more than one 
treatment episode in that year.
Table 1: No. of cases with alcohol as a main problem by treatment status, NDTRS 2011–2017
2011 2012 2013 2014 2015 2016 2017
n % n % n % n % n % n % n %
Total 8876 8609 7819 7760 7618 7643 7350
New cases 4645 52.3 4149 48.2 3708 47.4 3772 48.6 3553 46.6 3678 48.1 3500 47.6
Previously treated 4110 46.3 4353 50.6 3932 50.3 3807 49.1 3948 51.8 3783 49.5 3652 49.7
Treatment status 
unknown 121 1.4 107 1.2 179 2.3 181 2.3 117 1.5 182 2.4 198 2.7
15
Issue 70 | Sum
m
er 2019      drugnet IRELAND
Table 2: No. of treated cases with alcohol as a main problem, by type of service provider, NDTRS 2011–2017
2011 2012 2013 2014 2015 2016 2017
n % n % n % n % n % n % n %
Total 8876 8609 7819 7760 7618 7643 7350
Outpatient 4635 52.2 4510 52.4 4221 54.0 4133 53.3 4018 52.7 4005 52.4 3894 53.0
Inpatient* 3378 38.1 3309 38.4 2809 35.9 2803 36.1 2916 38.3 2994 39.2 2949 40.1
Low threshold† 591 6.7 519 6.0 521 6.7 605 7.8 480 6.3 495 6.5 436 5.9
Prison 272 3.1 271 3.1 268 3.4 219 2.8 204 2.7 149 1.9 71 1.0
* Includes any service where the client stays overnight, e.g. inpatient detoxification, therapeutic communities, respite and step-down.
† Low-threshold treatment programmes are harm reduction centres targeted at drug users.
Case characteristics 
In 2017, as in previous years, over one-half (53%) of cases were 
treated in outpatient facilities (see Table 2). In addition, 4 in 10 
cases (40.1%) were treated in residential settings, again similar 
to previous years.
The most recent data (i.e. 2017) show that the median age to 
start drinking for cases in treatment for problem alcohol use 
was 16 years, a trend that has remained steady over the seven-
year reporting period. Over this period, the proportion of cases 
classified as dependent increased from 58.8% in 2011 to 72% in 
2017. Dependent means that a person feels that they are unable 
to function without alcohol and the consumption of alcohol 
becomes an important – or sometimes the most important – 
factor in their life.2 A significant finding of the analysis was that 
in 2017 approximately two-thirds (66.8%) of new cases were 
classified as alcohol dependent. According to Dr Suzi Lyons, 
senior researcher at the Health Research Board, this means 
that ‘more people are presenting when the problem is already 
severe which makes treatment more complex and recovery 
more difficult’.
The median age of treated cases increased over the seven-year 
period from 38 years in 2011 to 41 years in 2017. The median age 
of new cases also continued to rise from 36 years in 2011 to 40 
years in 2017.
In 2017, over one-half (52.1%) of cases were unemployed, 
while the proportion of cases recorded as homeless increased 
from 6.2% in 2011 to 8.4% in 2017. Also, in 2017, 1.6% of cases 
identified as Irish Traveller; this compares with 0.7% of the 
general population in the latest census (Census 2016).3
One in five cases treated for problem alcohol use reported 
problem use of more than one substance (polydrug use) in 
2017. Cannabis (60.5%) was the most common additional 
drug reported in 2017, followed by cocaine (41.8%) and then 
benzodiazepines (22.9%). Cocaine increased from 28.8% in 2011 
to 41.8% in 2017. 
Case gender, 2017
The majority of cases in 2017 were male (64.9%), similar to 
previous years. The median age of treated cases for females 
(43 years) is higher than for males (40 years). This is further 
reflected in the median age for new cases entering treatment 
(38 years for males vs 43 years for females). Females also 
account for a higher proportion of cases in treatment aged 50 
years or over (31.6%) than males aged 50 years or over (25%). 
Homelessness was more prevalent among males (10.1%) than 
females (5.4%). 
In 2017, 74.2% of males were classified as alcohol dependent, as 
compared with 68.1% of females.
The proportion of cases with an additional other problem 
drug was higher for males (29.3%) than for females (16.6%). 
The four most common additional drugs (cannabis, cocaine, 
benzodiazepines, and opiates) for cases in alcohol treatment 
are the same for both males and females. There are, however, 
differences in the proportion reporting use of these drugs 
based on gender. 
The findings of this bulletin can be used to inform research, 
policy, and practice in the area of alcohol addiction and 
treatment in Ireland. 
Derek O’Neill
1 Health Research Board (2019) National Drug Treatment Reporting 
System 2011–2017 alcohol data. Dublin: Health Research Board. 
https://www.drugsandalcohol.ie/30202 
2 Health Service Executive (HSE) alcohol misuse definitions. For 
further information, visit:     
https://www.hse.ie/eng/health/az/a/alcohol-misuse/defining-a-
drink-problem.html
3 Data on ethnicity is taken from Census 2016 from the Central 
Statistics Office (CSO). For further information, visit:  
https://www.cso.ie/en/releasesandpublications/ep/p-cp8iter/
p8iter/p8e/
Alcohol treatment figures from 
the NDTRS, 2011–2017 continued
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9 Experience of the 
treatment demand 
indicator in Europe
The treatment demand indicator (TDI) is an epidemiological 
indicator, used in the European Union (EU), with the aim of 
providing a common format on collection and reporting of 
data on people seeking treatment for problem drug use. A 
recent study reviewed the implementation of the TDI and the 
data analysis and trends it has provided.1
The TDI is one of five key epidemiological indicators of the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). The TDI provides a common format that is used to 
collect specific information on the number, characteristics, 
and substance use patterns of drug users entering treatment 
in European countries. The information collected can provide 
data on general trends in problem drug use and treatment 
uptake and patterns. The information that is collected through 
the TDI is used to inform the yearly European Drug Report and 
the Statistical Bulletin. TDI data from Ireland are provided from 
the National Drug Treatment Reporting System to the EMCDDA, 
with the most recent data published in April 2019.2
Treatment data tend to be the primary source of information 
on the drug user population at national level, providing 
a substantial sample of the entire population with drug 
problems, making it a highly valuable data collection tool. 
Data are used to analyse the availability and accessibility 
of treatment services, providing important information for 
evaluation and planning of treatment services.
As the TDI collects standardised information, it enables 
analysis and comparisons to be made in treated problem drug 
use across European countries. The EMCDDA is responsible for 
the collection of data using the TDI and it coordinates this data 
collection through 30 national monitoring centres. In 2012, the 
TDI underwent a revision, whereby the current protocol used 
is TDI Protocol 3.0.3 
This review looked at the information collected through the 
TDI over the last 10 years and its implementation.
Key findings
Some of the most recent findings (for 2015 or the most 
recent year available) show that in 2015 some 29 EU countries 
reported data on 457,811 clients entering drug treatment 
from 6,846 drug treatment centres. Of these, 37% were 
first-time entrants to treatment; 80% of first-time treatment 
entrants were male, with a mean age of 33 years. Some 37% 
of the clients were unemployed (compared with 9.4% in the 
general population), 7% were homeless and/or without stable 
accommodation. In 2015, across Europe, opioids, mainly 
heroin, accounted for 38% of the clients, followed by cannabis 
at 31% and cocaine at 13%.
Trend analysis for the last 10 years has shown the changing 
pattern of drug use. Data for trend analysis in Europe are only 
available since 2006. In the period 2006–2015, the number 
of countries reporting TDI data rose from 27 to 29, and the 
number of clients increased from 396,349 to 467,811.
First-time treatment entrants between 2006 and 2015 
reporting the primary drug problem as opioids decreased from 
56,000 (37%) to 33,000 (21%). In most European countries, the 
number of first-time treatment entrants for primary cannabis 
use has consistently increased from about 43,000 (28% of all 
new drug clients) in 2006 to about 75,000 (47% of all new drug 
clients). Trend analysis is carried out for all reporting countries; 
however, significant differences to the general analysis can 
exist between individual countries. These country differences 
should be considered when reporting on European drug 
treatment demand data.
TDI data limitations
While the TDI provides important data and is a highly valuable 
tool, some of its data limitations should be considered. The TDI 
represents only a certain part of the drug treatment system, 
and this representation can vary significantly across the 
different countries. How data are collected can differ between 
countries and there can be fluctuations in data reporting due 
to the number and type of treatment centres reporting as well 
as the number of clients. Double counting also exists within 
the data, where individuals are registered more than once in 
the database, leading to an overestimation of the number of 
individuals in treatment. Another TDI limitation to consider 
is the restricted range of substances included in the data 
collection. Data are only collected on illicit drugs, no data 
on tobacco are collected, and information is only collected 
on alcohol if it is reported as a secondary drug for entering 
treatment. 
However, the TDI is the largest drug-related dataset in Europe, 
and is extremely useful for policymakers at European level. 
The common data collection tool enables drug treatment 
professionals to compare their national treatment data against 
other countries to try to improve national responses. It is an 
extremely important source of information providing evidence 
on the extent and patterns of drug use and treatment service 
utilisation across the EU, Norway, and Turkey. 
Helen Kennelly
1 Montanari L, Pirona A, Guarita B, Hedrich D and Mounteney J 
(2019) The experience of the treatment demand indicator in 
Europe: a common monitoring tool across 30 countries. J Stud 
Alcohol Drugs, Suppl s18: 139–51.    
https://www.drugsandalcohol.ie/30226/
2 Health Research Board (2019) National Drug Treatment Reporting 
System 2011–2017 drug data. Dublin: Health Research Board. 
https://www.drugsandalcohol.ie/30197/ and  
https://www.hrb.ie/publications 
3 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2012) Treatment demand indicator (TDI) Standard 
protocol 3.0: guidelines for reporting data on people entering 
drug treatment in European countries. Luxembourg: Publications 
Office of the European Union.    
https://www.drugsandalcohol.ie/18436/
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Experiences of 
people engaged 
in long-term 
methadone 
maintenance 
treatment
On 10 December 2018, the Dún Laoghaire Rathdown Drug and 
Alcohol Task Force (DLRDATF) launched their report, ‘Just 
maintaining the status quo’? The experiences of long-term 
participants in methadone maintenance treatment.1 The 
report documents the findings of a qualitative study examining 
the experiences of people engaged in long-term methadone 
maintenance treatment in the Dún Laoghaire Rathdown area of 
South Dublin. 
This is the first Irish study to specifically examine the 
experiences of individuals who are engaged in long-term 
methadone maintenance treatment. The study was conducted 
by a team of researchers from Trinity College Dublin, led by Dr 
Paula Mayock of the School of Social Work and Social Policy. 
The main study objective was to examine the lived experiences 
of people receiving methadone treatment, their social 
relationships, health, and social care needs. 
The study examined the experiences and perspectives of 25 
people (16 male, 9 female) who first accessed methadone 
treatment a minimum of 10 years ago, and who reported 
at least one episode of opioid substitution treatment since 
first accessing treatment. Study participants were recruited 
through services located in the Dún Laoghaire Rathdown area, 
including specialist addiction clinics, community and voluntary 
addiction services, primary care services, and supported 
temporary accommodation services. Interviews were 
conducted between August 2017 and February 2018. 
The average age of research participants was 43 years. Almost 
one-third (32%) of participants were aged 35–39 years; 56% 
were aged 10–49 years; and the remaining 12% were aged 50 
years or older. Almost two-thirds of participants (64%) had 
first accessed methadone maintenance treatment more than 
20 years previously. 
Key findings
• The majority of participants reported that methadone 
maintenance treatment had positively impacted at least 
one aspect of their lives. The most commonly reported 
benefit was stability and normality, with improved capacity 
to fulfil roles as parents, family members, and friends. 
• The average age of first drug use was 14 years of age, while 
the average age of first heroin use was 19 years of age.
• Levels of educational attainment were low among 
participants, with one in four (24%) having no educational 
qualifications and more than one-half (52%) not 
progressing beyond Junior Certificate level.
• Almost one-third of participants (32%) were homeless or 
living in unstable accommodation at the time of interview. 
More than one-half of the study participants (56%) had 
experienced homelessness at some point in their lives.
• Mental health problems, including depression, were widely 
reported among study participants. 
• Many reported having chronic illnesses, including hepatitis 
C, liver cirrhosis, and a range of respiratory, renal, and 
coronary diseases.
• Negative experiences were reported by many, including 
negative interactions with treatment services and health 
professionals, and little autonomy in their treatment 
progression, particularly in relation to long-term 
rehabilitation planning. 
• Stigma was a dominant experience reported by study 
participants. Stigma was reported on many levels, including 
within treatment settings and within the communities 
where people resided. Participants reported feeling 
stereotyped and disrespected within their treatment 
setting, and many reported attempting to conceal their 
methadone use and clinic attendance from family and 
friends. Other forms of stigma related to being an older 
person in treatment and fear of judgement or rejection 
due to continued engagement in treatment.
• Participants perceived themselves as stigmatised 
health-service users, with many feeling excluded from 
employment and having little prospect of further 
education. 
• Levels of social reintegration among participants were 
reported as extremely low. The majority reported being 
unemployed with no realistic prospect of employment. 
• Most participants did not have access to the economic, 
social or personal resources needed to support and 
sustain recovery.
Conclusions
The report shows the complexity and characteristics of people 
who are long-term participants in methadone maintenance 
treatment. The authors highlight issues experienced by 
this group, including physical and mental health problems, 
isolation, social exclusion, and loneliness. The authors note 
that age combined with long-term drug use and treatment 
careers indicate that this group have many challenging health, 
social, and economic needs. The report also highlights 
that although methadone treatment had a positive impact 
on the lives of the study participants, multifaceted and 
multidisciplinary supports, including education, training, 
housing and family welfare, are needed in order to achieve 
social reintegration.
Anne Marie Carew
1 Mayock P, Butler S and Hoey D (2018) ‘Just maintaining the status 
quo’? The experiences of long-term participants in methadone 
maintenance treatment. Dublin: Dún Laoghaire Rathdown Drug 
and Alcohol Task Force. https://www.drugsandalcohol.ie/30063/ 
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9 Client perspectives 
on barriers to 
progressing 
through methadone 
maintenance 
treatment in Ireland 
Opiate use disorder (OUD) is a problem worldwide.1 European 
statistics show that there are approximately 1.3 million high-risk 
opioid users in the EU, where opioids are found in 82% of fatal 
overdoses.2 The most recent Irish data from 2014 estimated 
that there were 18,988 opiate users in the Republic of Ireland, 
giving a rate of 6.18 per thousand population aged 15–64 years 
(95% CI: 6.09–6.98).3
Methadone has ideal properties for the long-term treatment of 
OUD. A single dose of methadone overpowers the symptoms of 
opioid withdrawal for 24–36 hours without producing analgesia, 
sedation or euphoria.4 In Ireland, at year-end 2016, there were 
80 Health Service Executive (HSE) methadone specialist centres 
in operation, treating 5,438 clients.5 However, of these clients, 
only 17 were appropriately stabilised and, as such, transferred 
to the lower-risk community setting. This represented only 
2.2% of the potential transferrable client population.
A recent Irish study aimed to identify reasons as to why clients 
remain ‘trapped’ in the high-risk, specialist clinical setting.6 In 
this research, published in the journal BMC Health Services 
Research, qualitative semi-structured interviews were 
undertaken with 17 clients of one of Ireland’s HSE Drug and 
Alcohol Services. Each client had a severe OUD and had spent 
on average 7.5 years engaging with the methadone maintenance 
treatment programme.
Results
Participants’ life journey prior to an OUD included adverse 
childhood experiences (ACEs) and early exposure to illicit drug 
use. It was found that factors resulting in clients initiating and 
sustaining an OUD involved continuous hardship into adulthood, 
mental illness, and concurrent benzodiazepine use disorder, 
with subjects stating that these often resulted in loneliness 
and lack of life purpose. Living environments, a mistaken 
understanding of their illness, and poor communication with 
allied health professionals further perpetuated their OUD. 
Participants stated that positive factors influencing periods 
of abstinence were familial incentives and a belief in the 
efficacy of methadone. Clients’ own suggestions for improving 
their journeys included employing a multisectorial approach 
to managing OUD and educating themselves and others on 
opioid agonist treatments. If clients were not progressing 
appropriately, they themselves suggested enforcing a ‘time-
limit’ to engage with the programme or for their treatment to 
be postponed.
Conclusions
The authors noted that methadone maintenance treatment 
is ideally placed to work collaboratively with public health in 
order to access and support vulnerable, high-risk individuals 
subjected to ACEs. They concluded that a cross-departmental, 
intergovernmental approach to address substance misuse 
as a societal issue as a whole is needed. In addition, it was 
recommended that subsequent work needs to be done on 
tackling vulnerable children’s exposure to illicit drug use, 
concurrent benzodiazepine use in individuals with OUD, 
their housing conditions, and their lack of life purpose and 
loneliness.
Seán Millar
1 Teoh Bing Fei J, Yee A and Habil MH (2016) Psychiatric 
comorbidity among patients on methadone maintenance therapy 
and its influence on quality of life. Am J Addict, 25(1): 49–55.
2 European Monitoring Centre for Drugs and Drug Addiction 
(2016) European drug report 2016: trends and developments. 
Luxembourg: Publications Office of the European Union.  
https://www.drugsandalcohol.ie/25579/ 
3 Hay G, Jaddoa A, Oyston J, Webster J and Van Hout MC (2017) 
Estimating the prevalence of problematic opiate use in Ireland 
using indirect statistical methods. Dublin: National Advisory 
Committee on Drugs and Alcohol.    
https://www.drugsandalcohol.ie/27233/
4 Stotts AL, Dodrill CL and Kosten TR (2009) Opioid dependence 
treatment: options in pharmacotherapy. Expert Opin 
Pharmacother, 10(11): 1727–40.
5 Department of Health (2016) Central Treatment List: summary 
report for HSE Mid-West clinic. Jan 2016–Dec 2016 inclusive. 
Dublin: Health Service Executive.
6 Moran L, Keenan E and Elmusharaf K (2018) Barriers to progressing 
through a methadone maintenance treatment programme: 
perspectives of the clients in the Mid-West of Ireland's drug 
and alcohol services. BMC Health Serv Res, 18(1): 911.   
https://www.drugsandalcohol.ie/30195/
Profiles of Irish 
psychiatric inpatients 
with no fixed abode
Recent research has shown that the number of emergency 
hospitalisations among those experiencing homelessness in 
Ireland has increased significantly in the last 10 years.1 The 
profile of those using emergency department services suggests 
that they are, in the main, chronically or episodically homeless 
and thus represent a relatively small proportion of the overall 
homeless population. Nevertheless, these subjects are heavy 
users of various costly services. Furthermore, a number of Irish 
studies have suggested that homeless people exhibit relatively 
high levels of mental health difficulties and may be over-
represented in psychiatric settings.1,2
Recent Irish research aimed to examine the profile of 
psychiatric admissions for subjects with no fixed abode.3 In 
this study, published in the Irish Medical Journal, the authors 
retrospectively evaluated the Health Research Board’s National 
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Psychiatric Inpatient Reporting System (NPIRS) data to develop 
an overview of admissions with no fixed abode recorded for the 
years 2007–2016 (n=2176). 
Results
It was found that in the 10-year period there was a 44% 
increase in admissions with no fixed abode from 188 in 2007 to 
271 in 2016. The analysis demonstrated that the characteristics 
of this cohort have remained largely unchanged in the 10 
years; almost three-quarters (1,598; 73.4%) were male, almost 
one-half (1,068; 49.1%) were less than 35 years of age, and 
three-quarters (1,638; 75.2%) were less than 45 years. Other 
characteristics of psychiatric inpatients with no fixed abode 
included the following:
• Three-quarters (1,643; 75.5%) were single and a similar 
proportion were unemployed (1,640; 75.4%). 
• 621 (28.5%) had a diagnosis of schizophrenia, 258 
(11.9%) had a depressive disorder, while 212 (9.7%) had a 
personality/behavioural disorder.
• 257 (11.8%) had an alcohol disorder, while 333 (15.3%) had 
other drug disorders.
Conclusions
The authors noted that these characteristics are consistent 
with the single ‘chronically homeless’ people described in the 
literature. In addition, it was observed that the prevalence of 
schizophrenia and alcohol and drug disorders differed from 
the national profile of psychiatric admissions.4 The authors 
concluded that there is a need to use routinely collected 
data to help understand and address the needs of specific 
homeless subgroups. In particular, it needs to address those on 
institutional circuits that include psychiatric inpatient facilities. 
Seán Millar
1 O’Sullivan E (2008) Researching homelessness in Ireland: 
explanations, themes and approaches. In Downey D (ed) 
Perspectives on Irish homelessness: past, present and future. 
Dublin: Homeless Agency. https://www.drugsandalcohol.ie/11723/ 
2 Keogh C, O’Brien KK, Hoban A, O’Carroll A and Fahey T (2015) 
Health and use of health services of people who are homeless 
and at risk of homelessness who receive free primary health care 
in Dublin. BMC Health Serv Res, 15(1): 58.   
https://www.drugsandalcohol.ie/23533/ 
3 Daly A, Craig S and O’Sullivan E (2019) A profile of psychiatric in-
patient admissions with no fixed abode (NFA) 2007–2016. Ir Med J, 
112(1): 853. https://www.drugsandalcohol.ie/30179/ 
4 Daly A and Craig S (2017) Irish psychiatric units and hospitals 
census 2016: main findings. Dublin: Health Research Board. 
https://www.drugsandalcohol.ie/26559/
Profiles of Irish psychiatric 
inpatients with no fixed abode 
continued
Public awareness 
of alcohol-related 
health conditions in 
Ireland: findings from 
the Healthy Ireland 
Survey
Alcohol is one of the leading causes of death and disability 
worldwide. A causal relationship has been established between 
alcohol and over 60 health conditions, such as female breast 
cancer, bowel cancer, and high blood pressure.1 Despite the 
growing evidence on the contribution of alcohol to the global 
burden of disease and mortality, research in other countries 
demonstrates poor public knowledge of the association 
between alcohol and a range of alcohol-related health 
conditions, including cancer.2,3 The aim of this research was 
to establish public knowledge of six alcohol-related health 
conditions in Ireland, namely liver disease, pancreatitis, 
stomach ulcers, high blood pressure, female breast cancer, and 
bowel cancer.
Methods
Data were generated from Wave 2 of the Healthy Ireland Survey, 
a nationally representative cross-sectional survey of adults 
aged 15 years or older in Ireland. A total of 7,498 respondents 
took part in Wave 2, with interviews completed between 
September 2015 and May 2016. More details on the sample 
and methodology can be found in the Healthy Ireland Wave 2 
technical report.4
Respondents’ knowledge of the link between the six 
alcohol-related conditions was measured by presenting the 
respondents with a showcard with the following question: 
‘Looking at this showcard, can you please tell me which of the 
following you are at increased risk of developing by drinking 
more than the recommended number of standard drinks in 
a week?’ The options presented on the showcard were: liver 
disease; pancreatitis; stomach ulcers; high blood pressure; 
female breast cancer; skin cancer; bowel cancer; all of 
these. The risk of developing skin cancer is not increased by 
consuming alcohol. The risk of all other conditions on the list is 
increased by drinking more than the recommended standard 
drinks in a week.
Findings
Respondents’ awareness of the six alcohol-related health 
conditions broken down by gender is displayed in Figure 1. 
With the exception of liver disease (90.5%), knowledge of the 
link between alcohol and all other alcohol-related conditions 
was poor, ranging from 21.2% for breast cancer to just over 
50% for high blood pressure. Some 14.1% of respondents 
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Figure 1: Proportion of males and females who reported selected health conditions are related to consuming more than the recommended 
number of standard drinks in a week
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Figure 2: Proportion of respondents who believe selected health conditions are related to consuming more than the recommended 
number of standard drinks in a week, broken down by age
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Public awareness of alcohol-
related health conditions  continued
identified alcohol consumption as a risk for developing skin 
cancer, despite no such evidence existing to support this 
link. Some 10.1% also incorrectly identified that ‘all of these’ 
conditions were related to excessive alcohol consumption. 
With the exception of high blood pressure, females’ awareness 
of alcohol-related conditions was slightly better than that of 
males. However, a higher proportion of females also incorrectly 
reported an association between alcohol consumption and skin 
cancer and ‘all of these’ conditions.
The age breakdown of responses is presented in Figure 2. 
For most of the alcohol-related health conditions, with the 
exception of bowel cancer, awareness was highest among those 
aged 35–64. Overall, the age differences were relatively small. 
In particular, however, the low awareness of alcohol-related 
conditions among the youngest age bracket is of concern given 
that they are the group which has been shown to report the 
highest rates of hazardous and harmful drinking patterns.5
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Conclusions
With the exception of liver disease, public awareness that 
alcohol can increase the risk of developing a variety of health 
conditions is low. Awareness varied greatly across specific 
conditions, with approximately one-half of the public being 
aware that increased alcohol consumption is linked to high 
blood pressure, compared with less than one-quarter being 
aware of the link between alcohol consumption and female 
breast cancer.
The poor public awareness of alcohol-related conditions and in 
particular of alcohol-related cancers is of concern. In Ireland, 
between 2001 and 2010, some 4,585 (4.7%) male and 4,593 
(4.2%) female invasive cancer diagnoses were attributable to 
alcohol, while 2,823(6.7%) of male cancer deaths and 1,700 
(4.6%) of female cancer deaths were attributable to alcohol.6 
Despite these figures, it is clear that the general public are not 
aware of the potential risks associated with increased alcohol 
consumption. The findings from this study provide support for 
the timely implementation of health warning labels on alcohol 
products as set out in the Public Health (Alcohol) Act 2018.
Claire O’Dwyer and Deirdre Mongan
1 Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SR, Tymeson 
HD, et al. (2018) Alcohol use and burden for 195 countries and 
territories, 1990–2016: a systematic analysis for the Global Burden 
of Disease Study 2016. Lancet, 392(10152): 1015–35.  
https://www.drugsandalcohol.ie/29555/
2 Buykx P, Gilligan C, Ward B, Kippen R and Chapman K (2015) 
Public support for alcohol policies associated with knowledge of 
cancer risk. Int J Drug Policy, 26(4): 371–79.
3 Buykx P, Li J, Gavens L, Hooper L, Lovatt M, de Matos EG, et al. 
(2016) Public awareness of the link between alcohol and cancer in 
England in 2015: a population-based survey. BMC Public Health, 
16(1): 1194. https://www.drugsandalcohol.ie/26464/
4 Ipsos MRBI (2016) Healthy Ireland Survey 2016: technical report. 
Dublin: Stationery Office.
5 Department of Health (2018) Healthy Ireland Survey 2018: 
summary of findings. Dublin: Stationery Office. 
https://www.drugsandalcohol.ie/29851/
6 Laffoy M, McCarthy T, Mullen L, Byrne D and Martin J (2013) 
Cancer incidence and mortality due to alcohol: an analysis of 
10-year data. Ir Med J, 106(10): 294–97. 
https://www.drugsandalcohol.ie/21068/
Public awareness of alcohol-
related health conditions  continued
RESPONSES
A systems 
perspective on drug 
prevention
In March 2019, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) published Drug prevention: exploring 
a systems perspective, as part of its Technical Report series.1 
Drawing on systems theory, the report considers substance use 
prevention in Europe through the lens of a system. A system 
is described as being made up of ‘a set of elements organised 
for a common purpose that are connected and interact with 
each other to form an integrated whole’ (p. 6). By taking this 
approach, the report highlights the wide range of factors that 
need to be considered when implementing substance use 
prevention programmes and policies.
Prevention system model
Data gathered from the Reitox National Focal Points, as part 
of the EMCDDA’s annual reporting cycle, were used to develop 
a model of an overall prevention system (see Figure 1). It is 
proposed as a starting point for comparing and analysing 
national or regional approaches to prevention, and reflects how 
prevention is conceived, organised, and delivered across the 
member states, as well as how the components interact.
The five commonly accepted components of a prevention 
Figure 1: Components of a prevention system
Moderators
Organisation
Research 
and quality 
control
Interventions
Workforce
Target 
population
Implementation 
at local level
Interaction 
with academia
Intersectorial 
cooperation
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system featured in the model are each explored in the report 
using analysis of the Reitox data. For the purpose of this article, 
each component is described alongside a selection of the 
related findings.
1. Organisation
The authors focus on three aspects of how prevention delivery 
is organised:
• Decision-making – where decision-making happens, how 
evidence is used in the process, and how local needs are 
assessed. In relation to the second, of these a need was 
identified for a better understanding of how research 
and policy interact, and for researchers to become more 
attuned to the needs of policymakers and practitioners. 
Having an assessment of local needs was described as a 
feature often lacking in the area of prevention, in particular 
when compared with the fields of treatment and harm 
reduction.
• Intersectorial cooperation – how/if it occurs and the 
conflicting views and priorities that exist. While there 
may formally be a drug coordinating role or body in a 
country, this did not necessarily result in coordination in 
practice. Barriers included the conflicting priorities within 
a country’s governing bodies; for example, between the 
revenue produced by the sale of addictive goods, such as 
alcohol, and the health costs associated with its use.
• Funding – how prevention is funded and why certain 
activities may be funded and not others. While the sources 
of funding for prevention across Europe varied, data 
on funding and how decisions are based on them was 
described as ‘scarce’ (p. 15).
2. Research and quality assurance
Having the capacity to translate scientific findings, effective 
interventions, and principles of effectiveness into practice and 
existing services is described as ‘one of the most vital features 
of a prevention system’ (p. 17). The authors identify a number of 
challenges in doing so, which include:
• A lack of knowledge among stakeholders about the 
evidence of what works in prevention.
• The focus of the (largely North American) evidence base on 
manualised activities presents challenges in the European 
context. A need is identified for more focus on how to 
translate evidence into practice and evidence on non-
manualised activities.
3. Interventions
The authors note that in order to be of use in the prevention 
field, the systems approach needs to take account of 
interventions of all forms (universal, selective, and indicated) 
and functions (developmental, environmental, and 
informational) that currently feature in the debate. They identify 
one of the main debates among prevention professionals in 
Europe to be ‘whether manual-based programmes should 
be scaled up or emphasis should instead be given to local 
solutions that fit the particular circumstances of the culture, 
problem and infrastructure’ (p. 21).
The prevention field in Europe and the range of interventions 
delivered is complex. Manual-based programmes, selective 
and indicated services, and environmental policies are 
discussed in this section of the report ‘to showcase the 
different perspectives and priorities that a systems approach 
to prevention is able to incorporate’ (p. 19). It was found that 
a distinctive feature of European prevention systems is that 
manual-based interventions often do not play a significant 
role. The authors explored the focus of each member state’s 
prevention activities, asking whether they focused more on 
environmental policies or manualised programmes; Ireland was 
found to put more emphasis on the former.
Another key issue identified under interventions was that 
while there is often overlap between the determinants 
of different problem behaviours (e.g. substance use and 
violence/delinquency) and therefore the possible prevention 
interventions that could affect change, because they fit under 
different political portfolios, these commonalities are not 
understood and opportunities to have an impact are missed.
4. Workforce
This component covers the numbers in the workforce, the 
types of individuals, and the skills they have. Overall, the 
prevention workforce is diverse and finding information on its 
composition and training was described as ‘difficult’ (p. 23). It 
was noted that there is no agreed means to monitor the quality 
of prevention work and there was no common professional 
profile of a prevention worker. The need for standards and 
training for those working in the area was highlighted.
5. Target population
The recipients of prevention are a critical component of any 
system, not only as recipients but also in the development of 
interventions. As mentioned above, assessing local needs is 
often lacking from prevention systems. Other issues identified 
that need to be considered when selecting suitable and 
relevant interventions included the level of social exclusion 
experienced by the target population and the acceptability of 
programmes by the target population.
Alongside the five components laid out above was a set 
of moderators that influence the interaction between the 
components. These included: social inequality; social capital; 
social norms; alcohol and tobacco policies; and drugs 
legislation.
Concluding comment
This report is not a ‘how to’ guide on prevention, but rather 
through the experiences of member states provides a useful 
starting point for looking at core components of prevention 
systems and how they interact. It raises a number of interesting 
themes for prevention in the Irish context. For example: 
promoting and advancing a comprehensive definition of 
prevention; making links between substance use prevention and 
other behaviours; the relationship between funding and quality 
assurance; skills development and training for prevention 
professionals; and decision-making about interventions at 
national, regional and local level.
Lucy Dillon
1 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) (2019) Drug prevention: exploring a systems 
perspective. Technical Report. Luxembourg: Publications Office 
of the European Union. https://www.drugsandalcohol.ie/30362/
A systems perspective on drug 
prevention  continued
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Second National 
Intracultural Health 
Strategy, 2018–2023
The Second National Intracultural Health Strategy (NIHS) 2018–
2023 has been published by the Health Service Executive (HSE).1 
It will enable the HSE to better address the needs of service 
users of all ethnic and cultural backgrounds. The strategy is 
in response to the increasing diversity of people living and 
accessing health services in Ireland. Census 2016 showed that 
17% of the population were not born in Ireland, representing 
500,000+ individuals from 200 different countries (p. 13).1
This strategy was developed through a process of consultation 
with community networks and sections within the HSE. The 
subsequent submissions were analysed and eight areas were 
identified, ranging from access to interpreting and translation, 
gender-based violence, and implementation of the second 
NIHS.2
Focus of first NIHS
The second strategy aims to build on the achievements of the 
first strategy (2007–2012).3 The first strategy looked to target 
access to services, develop the cultural competence of staff, 
and improve the evidence base around intracultural health 
needs. It was a comprehensive document that covered many 
of the key issues related to meeting the health needs of ethnic 
minority service users. Unfortunately, its publication coincided 
with the economic recession and significant restrictions on 
funding for many areas. Despite this, in 2016, a review of the 
strategy showed that 20 of its 43 actions had been completed. 
Achievements were made, for example, in capacity building, 
cultural competence of staff, and development of culturally 
appropriate resources. The least progress was made in the 
key area of data collection and analysis, even though this 
was identified as a key pillar of the first strategy. Of note, the 
National Drug Treatment Reporting System (NDTRS) is one of 
the few national data collection systems to successfully collect 
aggregated data on ethnicity (including Roma), country of birth, 
and main language.4
Focus of second NIHS
The focus of the first strategy was concentrated on newly 
arrived ethnic minority people, often seeking international 
protection. The second strategy seeks to address the 
healthcare needs of migrants5 who have made Ireland their 
home not only in recent times but over the past few years, as 
well as members of the Traveller and Roma communities. In 
2017, the Department of Justice and Equality published the 
National Traveller and Roma Inclusion Strategy, 2017–20216 
specifically for these communities and, while the NIHS does 
not seek to duplicate actions, Roma in particular are also 
highlighted in this strategy in relation to their health needs.
Implementation: goals and objectives
There will be a detailed implementation plan for the strategy 
with the aim of reviewing progress mid-term in 2020/2021. The 
goals and objectives of the second strategy (2018–2023) are 
reproduced below (p. 21).
Goal 1
Enhance accessibility of services to service users from diverse 
ethnic, cultural and religious backgrounds.
Strategic objectives:
• Provide information in accessible, culturally responsive 
ways.
• Develop a model for interpreting provision across the HSE.
• Develop an evidence-informed system of translating 
information.
Goal 2
Address health issues experienced by service users from 
diverse ethnic, cultural and religious backgrounds.
Strategic objectives:
• Implement cross-government obligations in respect of 
health needs of service users.
• Implement national obligations in relevant cross-
departmental strategies.
• Promote a model of health screening and prevention.
• Address health inequalities relevant to service users in 
relation to oral health, sexual health, reproductive health, 
children and young people, LGBTI+, disability, men, mental 
health and palliative care.
Goal 3
Ensure provision of high-quality, culturally responsive services 
to service users from diverse ethnic, cultural and religious 
backgrounds.
Strategic objectives:
• Provide intercultural awareness training to all relevant staff, 
and take into account the needs of staff who work with a 
diverse population.
• Ensure that services are planned and delivered in a context 
of cultural competence and in line with requirements of the 
public sector duty and related obligations.
Goal 4
Build an evidence base.
Strategic objective:
• Work towards the development of high-quality data 
collection, monitoring and evaluation to build an evidence 
base on minority ethnic health and ensure evidence-
informed practice.
Goal 5
Strengthen partnership working to enhance intercultural health.
Strategic objective:
• Actively promote participation of service users from 
minority ethnic groups in the design, planning, delivery and 
evaluation of services.
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Suzi Lyons
1 Health Service Executive (HSE) (2018) Second National 
Intracultural Health Strategy 2018–2023. Dublin: HSE. Available 
online at:  
https://www.hse.ie/eng/about/who/primarycare/socialinclusion/
intercultural-health/intercultural-health-strategy.pdf
2 An overview of the consultation process can be found on 
pages 38 and 39 of the strategy, along with a summary of the 
submissions and analysis of the consultation in Appendix 4 (p. 
100).
3 Health Service Executive (HSE) (2008) National Intracultural 
Health Strategy 2007–2012. Dublin: HSE. Available online at: 
https://www.hse.ie/eng/services/publications/socialinclusion/
national-intercultural-health-strategy-2007---2012.pdf
4. For further information on the NDTRS, visit:    
https://www.hrb.ie/data-collections-evidence/alcohol-and-
drug-treatment/how-data-is-collected/
5 The term ‘migrant’ is defined by the International Organization 
for Migration (IOM) as ‘any person who is moving or has moved 
across an international border or within a State away from his/
her habitual place of residence, regardless of (1) the person’s legal 
status; (2) whether the movement is voluntary or involuntary; (3) 
what the causes for the movement are; or (4) what the length of 
the stay is’. For further information, visit:   
https://www.iom.int/who-is-a-migrant
6 Department of Justice and Equality (2017) National Traveller 
and Roma Inclusion Strategy 2017–2021. Dublin: Department of 
Justice and Equality. Available online at:   
http://www.justice.ie/en/JELR/National%20Traveller%20
and%20Roma%20Inclusion%20Strategy,%202017-2021.pdf/
Files/National%20Traveller%20and%20Roma%20Inclusion%20
Strategy,%202017-2021.pdf
Second National Intracultural 
Health Strategy, 2018-2023  continued
• Engagement with other policing jurisdictions and agencies
• Implementation reports on Changing policing in Ireland 
(2015)3
• Desk-based research.
Issues raised
The local policing issues raised by the terms of reference were 
categorised thematically into four areas: strategic perspective; 
resource allocation, availability and use; resource deployment 
and capability; and delivering local services. What follows 
are examples of some of the key issues identified by the 
Inspectorate within these categories.
Strategic perspective
This section examined the factors that impact on the 
demand for policing services, how it is understood, assessed, 
and managed from a strategic perspective. The report 
identified changes in Ireland’s demographic profile along with 
environmental factors, such as serious and organised crime, 
climate change and Brexit, as areas that influenced policing 
priorities. To address these issues effectively and to determine 
the most appropriate strategy and workforce required, it is 
critical that AGS understands and measures the demand for 
its services. The importance of drawing on intelligence-led 
policing was emphasised, particularly in the area of threat, risk, 
and harm assessment to help prioritise policing actions. At the 
time of this review, this was not done in Ireland.
Resource allocation, availability and use
How Garda resources were used and allocated to provide 
effective, visible and responsive services to the community 
was examined. The review indicated that AGS does not 
have an appropriate human resource system to assist in the 
assignment and management of staff. Gardaí are currently 
assigned to divisions via the Cohort allocation model, which 
considers factors such as population, number of stations, 
and crime and non-crime incidents recorded on PULSE. 
This is not an evidence-based model. Notably, at the time 
of this review, data from Cohort indicated that the number 
of gardaí allocated to divisions was either in excess or lower 
than what was operationally required. Moreover, it was also 
evident that the number of gardaí on duty was inadequate to 
Policing with local 
communities
In December 2018, the Minister for Justice and Equality 
published the Garda Inspectorate’s Policing with local 
communities report.1 The Policing Authority (PA) was tasked 
with overseeing this review and worked alongside the Garda 
Síochána Inspectorate (GSINSP), who are responsible for 
ensuring that the resources available to An Garda Síochána 
(AGS) ‘are used so as to achieve and maintain the highest 
levels of efficiency and effectiveness in its operation and 
administration, as measured by reference to the best standards 
of comparable police services’ (s. 117).2 The terms of reference 
agreed by PA and GSINSP examined:
• The changing environments in rural, developing urban and 
suburban areas
• Views of local communities
• Allocations of Garda resources and their deployment at the 
local policing level, including the use of the Garda Reserve, 
Garda facilities and Garda equipment, and
• Relevant recommendations made in previous Inspectorate 
reports (p. 2).
Methodology
Over 40 areas were examined in the course of this investigation. 
Data were collected using a range of methods and analysed, for 
example:
• Formal information and data requests to AGS
• Statistical data from the PULSE (Police Using Leading 
Systems Effectively) system
• Self-report questionnaires
• Field visits to headquarters, divisions (n=8), districts, and 
national units
• Meetings with key stakeholders
• Public consultations and meetings attended on the future 
of policing in Ireland
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meet local policing needs, particularly in rural areas. Despite 
previous recommendations by the Inspectorate in 2015, a large 
number of trained members were still in non-operational 
posts instead of carrying out frontline duties. Moreover, gardaí 
were constantly taken away from core duties, rendering them 
unavailable for patrol or visibility. With regard to custody 
facilities, many do not have the right equipment and are not in 
secure areas.
Resource deployment and capability
The Inspectorate examined how AGS identified local demand 
and how it determined whether resources should be deployed 
to provide a visible, effective and responsive service locally. 
Barriers identified that prevented good resource planning and 
demand management included poor-quality service calls and 
data due to inconsistent recording by members, particularly 
for domestic incidents. While there was some evidence of 
good practice for structured briefing, tasking, and debriefing, 
generally this practice was absent. In contrast to other 
jurisdictions, duty planning in AGS is paper based, managed 
district by district, and the existing Garda rota uses a one-size-
fits-all approach. The report indicated that no national policy 
exists to determine how different types of service calls nor 
different types of crimes for investigation should be assigned. 
Moreover, vulnerability of victims is only aligned to certain 
crime types and support is only provided to victims that meet 
Garda policy vulnerability criteria.
Delivering local services
Engagement with communities and stakeholders and how AGS 
responds in the delivery of services were examined. While 
positive steps were being taken to include communities in 
policing and to make areas safer, this was not coordinated at a 
national level. In addition, the approaches used varied. Public 
consultation was evident; however, opportunities to implement 
a more interactive approach was underdeveloped. Positively, 
as per previous Inspectorate recommendations, practices and 
procedures for engaging with victims of crime have improved. 
For example, Garda Victims Services Offices have been 
introduced in all divisions and PULSE has been modified to 
record details of contact with victims. That being said, policies 
and procedures to support repeat victims of crime have not yet 
been implemented. The issue of rural crime and fear of crime 
has also been raised. The geography and rural isolation cause 
problems for AGS, which is further exacerbated by station 
closures in rural areas and reduced availability of community 
policing gardaí.
Critical actions
The Inspectorate identified nine critical actions that are 
considered essential to ensuring that Irish policing services 
provided to the community are efficient, visible, accessible and 
responsive:
1 Evidence-based methodologies and processes that enable 
AGS to understand current and future demand and inform 
identification of its policing priorities
2 Organisational structures, strategies and plans that enhance 
the delivery of local policing services
3 Evidence-based resourcing model that allows accurate 
allocation of resources based on policing need in areas of 
Policing with local communities  
continued
higher threat, risk, harm, and vulnerability
4 Organisational visibility and accessibility strategy, supported 
by divisional implementation plans to enhance public 
confidence and take policing to the public
5 Maximum availability of human resources at local policing 
levels
6 Policies, processes and systems to ensure effective 
deployment of resources at a local level
7 Capability of the local policing workforce through 
the provision of relevant training programmes, better 
supervision, and the use of new technologies
8 Strategies, processes and action plans to improve delivery 
of local policing services
8a New guidance and training and funding for Joint Policing 
Committees and local community to provide increased 
accountability for and support to local policing
9 Implementation of a full divisional model.
Conclusions
While critical actions were put forward, Chief Inspector Mark 
Toland of the Inspectorate stated that ‘the Garda Síochána 
do many things well and their strong community ethos was 
reflected throughout this inspection and forms a strong 
foundation to develop a more structured and consistent 
approach to preventing harm in communities’ (p. 1).4 The 
Minister for Justice and Equality has requested that this report 
should be referred to and considered in the work carried out 
by the Garda Commissioner and the Implementation Group 
on Policing Reform.4 This report was welcomed by the Policing 
Authority who believe that it will make an extensive contribution 
to the ongoing work in this area.5
Ciara H Guiney
1 Garda Síochána Inspectorate (2018) Report of the Garda 
Síochána Inspectorate: policing with local communities. Dublin: 
Garda Síochána Inspectorate.    
https://www.drugsandalcohol.ie/30115/
2 Government of Ireland (2005) Garda Síochána Act 2005. 
Available online at:      
http://www.irishstatutebook.ie/eli/2005/act/20/enacted/en/
print.html
3 Garda Síochána Inspectorate (2015) Report of the Garda 
Síochána Inspectorate: changing policy in Ireland. Dublin: Garda 
Síochána Inspectorate. https://www.drugsandalcohol.ie/29426/
4 Garda Síochána Inspectorate (2018) Press release: publication of 
Garda Inspectorate Report ‘Policing with Local Communities’. 
Dublin: Garda Síochána Inspectorate. Available online at: http://
www.gsinsp.ie/en/GSINSP/Pages/press_releases
5 Policing Authority (2018) Publication of Garda Inspectorate report 
‘Policing with local communities’. Dublin: Policing Authority. 
Available online at: https://www.policingauthority.ie/en/all-
media/news-detail/publication-of-garda-inspectorate-report-
policing-with-local-communities
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9 End-of-life care for 
people with alcohol 
and drug problems
This rapid evidence assessment set out to determine the 
availability and quality of international research evidence on 
the subject of end-of-life care for people with alcohol and 
drug problems.1 There have been significant changes in the 
population of people with substance use problems. These 
include an increase in the number of older drug users and 
deaths in this population that are non-drug related and an 
increase in alcohol-related morbidity and mortality in older 
users. 
The review gathered together any research/evidence in 
the current responses to end-of-life care for this cohort, 
identifying gaps in the evidence, highlighting examples of good 
practice, and suggesting future directions for the research.
A significant gap in evidence on this topic was quickly identified, 
with a complete lack of evidence specifically on effective 
interventions, responses or models of practice, with no 
agreement as to what constitutes best practice for this group 
of people. As a result, the authors had to broaden their scoping 
of the evidence and instead produced a systematic map of the 
evidence available.
A final sample of 60 papers was included in this evidence 
review. Of these 60 papers, 32 reported empirical evidence. 
Applying quality assessment measures to these 32 papers, 9 
were determined to be of high quality, 18 were of moderate 
quality, and 5 were of low quality. Most of the papers came 
from North American countries, with two-thirds of the papers 
quantitative in approach. Only 11 of the papers were qualitative 
studies. Three main areas/themes were covered in these 
papers, namely, pain management, homeless and marginalised 
populations, and alcohol related.
Recommendations
The systematic map highlighted the significant gap in research 
and evidence in this area, with a particular gap in qualitative 
evidence from either service users or providers. Of the papers 
covered in this review, recommendations on best practices that 
were contained within the papers were gathered. There were 
some common recommendations relating to safe and effective 
pain management strategies and harm reduction strategies. 
Some of the recommendations for pain management included 
the use of screening tools and active monitoring of people 
using substances. For alcohol-related issues, recommendations 
included highlighting the need for awareness of alcohol 
withdrawal at the end of life and the need for routine alcohol 
assessment among these patients. Recommendations looking 
at homeless substance users included the provision of alcohol 
and care in shelter environments, safety plans, and supervised 
drug consumption.
Challenges and evidence gaps
This review also highlighted some of the challenges faced by 
care workers providing services in this area, which may have 
an impact on implementing the recommendations above. 
There were concerns about achieving safe and effective pain 
management in the context of a person’s substance abuse 
and managing ‘lifestyle factors’ that may be associated with 
substance abuse. These may involve certain behaviours, 
experiences, and anxieties that people bring to the service 
and can be difficult to manage. The review also highlighted the 
underutilisation of primary care services in this population but 
with a subsequent overutilisation of emergency services, with 
short admissions and premature self-discharge. This trend 
leads to receiving terminal diagnoses at a late stage of the 
disease, reducing the ability to plan for high-quality care in this 
area. 
The significant gaps identified in this review clearly show that 
this is an area where further research is needed to provide a 
better evidence base, which will help to develop better end-of-
life care for people with alcohol and drug problems. 
Helen Kennelly
1 Witham G, Peacock M and Galvani S (2018) End of life care 
for people with alcohol and drug problems: rapid evidence 
assessment. Manchester: Manchester Metropolitan University. 
https://www.drugsandalcohol.ie/30056/
Opioid dependence: 
buprenorphine 
prolonged-release 
injection (Buvidal)
An evidence summary was commissioned by Public 
Health England to examine the therapeutic potential of 
buprenorphine prolonged-release injection as an alternative 
opioid dependence treatment to the current treatment of 
daily sublingual buprenorphine-naloxone.1 Buprenorphine 
prolonged-release injection is an opioid agonist/antagonist and 
is administered as a weekly or monthly subcutaneous injection. 
Buprenorphine injection may be an alternative treatment 
option for opioid addiction where people have difficulties 
following a daily supervised opioid substitution and also where 
there is a potential safety risk of storing medicines at home. 
A recent randomised control trial2 demonstrated that, overall, 
people using buprenorphine prolonged-release injection were 
no less likely to have opioid-negative urine samples or respond 
to treatment in comparison with people receiving sublingual 
buprenorphine-naloxone. Similar adverse effects were 
reported for both treatments. A major safety issue to consider 
is the long duration of action of buprenorphine with the 
prolonged release of the injection, when considering the length 
of treatment needed to reverse the effects of overdose. 
The trial evidence presented has certain limitations. The trial 
was conducted in United States healthcare settings, with only 
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one of the study sites a primary care setting. This may limit the 
applicability of this treatment in these settings. The primary 
outcomes assessed from the trial were disease orientated. 
Patient-orientated outcomes, such as craving and withdrawal 
scores, were investigated as exploratory outcomes only. As 
participants were paid to take part in this study, the reported 
retention rates may not accurately reflect retention rates in 
practice. 
Mental health, pharmacy, medicines management, and health 
and justice specialists were asked for their views on using 
buprenorphine prolonged-release injection in practice. They 
stated that it may be an alternative treatment option in certain 
cases, but suggested barriers to its use. Some of these included 
the cost of injection, training and additional staff resources, 
lack of clarity about treating overdose, and service user 
preference.
For service users, some of the suggested advantages included 
service user convenience, reduced accidental poisonings, and 
a greater flexibility to engage in work or study. While some of 
the disadvantages include the need to attend a clinic for the 
injection and a reduction in pharmacy interaction, leading to a 
potential reduction in the ability to quickly identify health issues 
with the service user. 
Overall, buprenorphine prolonged-release injection is a 
possible alternative therapy for a specific small cohort. 
However, a significant change in the care pathway would 
be needed to facilitate this instead of the usual sublingual 
treatment. 
Helen Kennelly
1 National Institute for Health and Care Excellence (NICE) (2019) 
Opioid dependence: buprenorphine prolonged-release injection 
(Buvidal). London: NICE.     
https://www.drugsandalcohol.ie/30270/
2 Lofwall MR, Walsh SL, Nunes EV, et al. (2018) Weekly and monthly 
subcutaneous buprenorphine depot formulations vs daily 
sublingual buprenorphine with naloxone for treatment of opioid 
use disorder: a randomized clinical trial. JAMA Intern Med, 178(6): 
764–73. 
Buprenorphine prolonged-
release injection  continued
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Service report, 2018
The Health Service Executive (HSE) Adolescent Addiction 
Service (AAS) provides support and treatment in relation to 
alcohol and drug use for young people and families from the 
Dublin suburbs of Ballyfermot, Clondalkin, Palmerstown, Lucan, 
and Inchicore. Services provided include advice, assessment, 
counselling, family therapy, professional consultations, and 
medications if required. In 2018, the AAS published a report 
detailing referrals for 2017.1
Referrals
In 2017, the AAS worked with 44 young people and their 
families, with a mean age of 15.5 years (range: 14–18 years). This 
figure includes new referrals, re-referrals and continuances. 
The majority (84%) were male and 9% were non-Irish 
nationals. In terms of referral areas, the greatest numbers of 
referrals were from Clondalkin (48%) followed by Lucan (23%), 
Ballyfermot (20%), Inchicore (7%), and Palmerstown (2%).
Drug and alcohol use
Cannabis/weed continued to be the main substance 
used by clients at 97%, while alcohol use was at 95% (see 
Figure 1). Other substances of use included cocaine (48%), 
benzodiazepines (46%), amphetamines (39%), LSD (7%), 
ketamine (7%) and opiates (4%) (including heroin and 
Solpadeine). Solvents and head-shop-type products did not 
feature among young people’s substance use in 2017. The 
report noted that the biggest change concerning secondary 
drug use related to an increase in alcohol use by 35%, cocaine 
use by 19%, benzodiazepines by 13%, and amphetamines by 8%.
Other issues
Other issues presented related to indebtedness (30%) and 
absconding (40%), resulting in two young people accessing out-
of-hours services. Additionally, seven young people had social 
work involvement and four had residential care placements. 
Hospital admission was high at 14% and 14% of people had a 
history of self-harm. Of those who exited treatment, 58% had a 
planned discharge, 27% declined further treatment, while 15% 
moved out of the community or returned to their community 
of origin. Of those who had planned discharges, less than 5% 
had onward referral to residential treatment or long-term 
residential aftercare. The majority of young people (82%) were 
seen by a family therapist only, with 18% having a psychiatric 
assessment.
Conclusions
The AAS report authors noted that, as in previous years, most 
young people had established patterns of substance use prior 
to referral (range: 1 month–4 years) and, as a consequence, 
some struggle to maintain a drug-free status. Nevertheless, 
most achieve stability and several remain abstinent. They 
concluded that there is a need for parents and non-parental 
adults to identify young people within risk groups at an early 
stage and to elevate concern for them.
Seán Millar
1 Adolescent Addiction Service (2018) Adolescent Addiction Service 
report 2018. Dublin: Health Service Executive.  
https://www.drugsandalcohol.ie/29358/ 
Figure 1: Main substances used by AAS clients, 2017
Percentage (%)
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Source: HSE AAS, 2018
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Recent publications
Mental healthcare interfaces in a regional Irish prison
Gulati G, Otuokpaikhian K, Crowley M, Pradeep V, Meagher D 
and Dunne CP (2019) International Journal of Prisoner Health, 
15(1): 14–23. 
https://www.drugsandalcohol.ie/30319/
The purpose of this paper is to study the demographic, clinical 
characteristics and outcomes for those prisoners referred to 
secondary mental healthcare in a regional Irish prison and the 
proportion of individuals diverted subsequently from prison to 
psychiatric settings.
The multifaceted need set of those referred strengthens 
the argument for the provision of multidisciplinary mental 
healthcare into prisons. The analysis of security needs for those 
diverted from prisons supports the need for Intensive Care 
Regional Units in Ireland.
The association between self-harm and area-level 
characteristics in Northern Ireland: an ecological study
Griffin E, Bonner B, Dillon CB, O’Hagan D and Corcoran P (2019) 
European Journal of Public Health, Early online.
https://www.drugsandalcohol.ie/30361/
This study took an ecological approach to examine the 
association between area-level factors and rates of self-harm 
in Northern Ireland.
These findings indicate that self-harm rates are highest for 
those residing in highly deprived areas, where unemployment, 
crime and low level of education are challenges. Community 
interventions tailored to meet the needs of specific areas may 
be effective in reducing suicidal behaviour.
Alcohol industry CSR organisations: what can their Twitter 
activity tell us about their independence and their priorities? 
A comparative analysis
Maani Hessari N, van Schalkwyk MCI, Thomas S and Petticrew 
Mark (2019) International Journal of Environmental Research 
and Public Health, 16(5): 892.
https://www.drugsandalcohol.ie/30363/
We conducted a content analysis of the health information 
disseminated by AI [alcohol industry]-funded organisations 
through Twitter, compared with non-AI-funded charities, to 
assess whether their messages align with industry and/or public 
health objectives.
These findings are consistent with previous evidence that the 
purpose of such bodies is the protection of the alcohol market, 
and of the alcohol industry’s reputation. Their messaging 
strongly aligns with AI corporate social responsibility [CSR] 
goals. The focus away from health harms, particularly cancer, is 
also consistent with previous evidence. The evidence does not 
support claims by these alcohol-industry-funded bodies about 
their independence from industry.
Progress in adolescent health and wellbeing: tracking 
12 headline indicators for 195 countries and territories, 
1990–2016
Azzopardi PS, Hearps SJC, Francis KL, Kennedy EC, Mokdad AH, 
Kassebaum NJ, et. al (2019) Lancet, 393(10176): 1071–76.
https://www.drugsandalcohol.ie/30368/
Here, we present country-level estimates of 12 headline 
indicators from the Lancet Commission on adolescent health 
and wellbeing, from 1990 to 2016.
Although disease burden has fallen in many settings, 
demographic shifts have heightened global inequalities. 
Global disease burden has changed little since 1990 and the 
prevalence of many adolescent health risks have increased. 
Health, education, and legal systems have not kept pace with 
shifting adolescent needs and demographic changes. Gender 
inequity remains a powerful driver of poor adolescent health in 
many countries.
National Drugs Library
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Profiling emergency department presentations of 
14–15-year-olds in modern Ireland
Martin T, Corcoran A, Canty N, Dillon J, O’Reilly P, O’Donnell G, 
et al. (2019) Irish Journal of Medical Science, Early online.
https://www.drugsandalcohol.ie/30377/
Mid-adolescence, that twilight era when the human child 
transitions to adulthood, is an often overlooked developmental 
age yet harbours a subpopulation of patients with their own 
myriad of medical problems somewhat unique to their age 
group.
The results highlight the most common presentations of this 
subgroup of patients, with trauma, in keeping with recent 
international data, being the most common presentation. 
The noted high frequency in the number of mental health/
intoxication/self-harm presentations among the Irish teenagers 
in our region is consistent with trends reported in world 
literature and serves to emphasise one of the main challenges 
facing those working in paediatrics in Ireland over the next 10 
years.
‘HepCheck Dublin’: an intensified hepatitis C screening 
programme in a homeless population demonstrates the need 
for alternative models of care
Lambert JS, Murtagh R, Menezes D, O’Carroll A, Murphy C, 
Cullen W, et al. (2019) BMC Infectious Diseases, 19(1): 128.
https://www.drugsandalcohol.ie/30408/
The HepCheck study sought to investigate and establish 
the characterisation of HCV burden among individuals who 
attended an intensified screening programme for HCV in 
homeless services in Dublin, Ireland.
This study demonstrates that the current hospital-based 
model of care is inadequate in addressing the specific 
needs of a homeless population and emphasises the need 
for a community-based treatment approach. Findings are 
intended to inform HepCare Europe in their development of 
a community-based model of care in order to engage with 
homeless individuals with multiple co-morbidities including 
substance abuse, who are affected by or infected with HCV.
Cross-sectional study on the need to provide contraceptive 
services to women attending opioid-substitution therapy
Olioff J, O’Shea T, Horan A, Naughton AM and O’Brien D (2019) 
Heroin Addiction and Related Clinical Problems, Early online.
https://www.drugsandalcohol.ie/30420/
This study aimed to assess the pregnancy history, contraceptive 
use and access to contraceptive services of women attending 
Cork-Kerry Community Healthcare (CKCH) for opioid 
replacement therapy. The need for a contraceptive service 
within the Addiction Services at CKCH was evaluated.
This study highlights the need to increase contraceptive 
services for women attending CKCH for opioid replacement 
therapy. Addiction services are ideal locations to also access 
contraceptive services because service-users already attend 
these clinics frequently for treatment, and thus have continuity 
of care with healthcare providers.
Is policy ‘liberalization’ associated with higher odds of 
adolescent cannabis use? A re-analysis of data from 38 
countries
Stevens A (2019) International Journal of Drug Policy, 66: 94–99. 
https://www.drugsandalcohol.ie/30392/
The aim of this paper was to test the validity and reliability 
of Shi et al.’s conclusion that the HBSC [Health Behaviour in 
School-Aged Children] data show an association between 
policy ‘liberalization’ and increased likelihood of adolescent 
cannabis use.
Using a larger and more theoretically relevant sample of the 
HBSC respondents and an improved statistical model shows 
that the HBSC data do not reveal a statistically significant 
association between policy ‘liberalization’ and higher odds of 
adolescent cannabis use.
European Pain Federation (EFIC) position paper on 
appropriate use of cannabis-based medicines and medical 
cannabis for chronic pain management
Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, 
Morlion B, et al. (2018) European Journal of Pain, 22(9): 
1547–64.
https://www.drugsandalcohol.ie/30410/
This position paper provides expert recommendations for 
nonspecialist and specialist healthcare professionals in Europe, 
on the importance and the appropriate use of cannabis-based 
medicines as part of a multidisciplinary approach to pain 
management, in properly selected and supervised patients.
Codeine usage in Ireland – a timely discussion on an 
imminent epidemic
McDonnell E (2019) Irish Medical Journal, 112(3): 899.
https://www.drugsandalcohol.ie/30373/
From a dual perspective as both a current medical student 
and practising community pharmacist, I note that codeine 
is an addiction that is often hidden under the guise of pain 
management, going unaddressed by both doctor and patient. 
Pain is a very common complaint in primary care settings in 
Ireland and the UK.
Recent publications continued
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Excellent reliability and validity of the Addiction Medicine 
Training Need Assessment Scale across four countries
Pinxten WJL, Fitriana E, De Jong C, Klimas J, Tobin H, Barry T, et 
al. (2019) Journal of Substance Abuse Treatment, 99: 61–66. 
https://www.drugsandalcohol.ie/30292/
The aim of this study was to evaluate the psychometric 
properties of the addiction medicine AM-TNA Scale: an 
instrument specifically designed to develop the competence-
based curriculum of the Indonesian AM course.
In our study the AM-TNA scale had a strong two-factor 
structure and proved to be a reliable and valid instrument. The 
next step should be the testing external validity, strengthening 
discriminant validity and assessing the re-test effect and 
measuring changes over time.
Epidemiology, clinical features and management of patients 
presenting to European emergency departments with acute 
cocaine toxicity: comparison between powder cocaine and 
crack cocaine cases
Miró O, Dargan PI, Wood DM, Dines AM, Yates C, Heyerdahl F, et 
al. (2019) Clinical Toxicology, 57(8): 718–26.
https://www.drugsandalcohol.ie/30207/
The aim of this study was to analyse the epidemiology, clinical 
picture and emergency department (ED) management of a large 
series of patients who presented to European EDs after cocaine 
consumption, comparing data from powder (C1 group) and 
crack (C2 group) consumers.
Cocaine is commonly involved in European ED presentations 
with acute recreational drug toxicity, but there is variation 
across Europe not just in the involvement of cocaine but in the 
proportion related to powder versus crack. Some differences 
in clinical picture and ED management exist between powder 
cocaine and crack consumers.
You’re with your ten closest mates … and everyone’s kind 
of in the same boat’: friendship, masculinities and men’s 
recreational use of illicit drugs
Darcy C (2018) AMITY: The Journal of Friendship Studies, 5(1): 
43–57.
https://www.drugsandalcohol.ie/30254/
Based on empirical sociological research, this article explores 
how some Irish men’s recreational use of illicit drugs, 
masculinities and friendship, interconnect. Drawing from 
in-depth interviews with twenty Irish men who identified 
as recreational users of illicit drugs, the article examines 
men’s drug taking within homosocial contexts as a friendship 
practice. By conceptualising masculinities as relational, socially 
constructed and fluid, the article examines social aspects of 
men’s drug taking as part of a pattern of gender practices used 
to establish, maintain and affirm men’s friendships. The findings 
of the research demonstrate men’s recreational use of illicit 
drugs forms part of the social practices of friendship among 
drug taking men, and men’s understandings of masculinity in 
turn influence these social practices.
Recent publications continued
Trends in addiction treatment in Irish prisons using national 
surveillance data, 2009–2014
Cannon A, Nally F, Collins A, Fay R and Lyons S (2019) 
International Journal of Prisoner Health, 15(2): 105–113.
https://www.drugsandalcohol.ie/30318/
The purpose of this paper is to analyse trends in addiction 
treatment demand in prisons in Ireland from 2009 to 2014 using 
available national surveillance data in order to identify any 
implications for practice and policy.
This is the first study to analyse treatment episodes in prison 
using routine surveillance data in Ireland. Analysis of these 
data can provide useful information, not currently available 
elsewhere.
The interaction between maternal smoking, illicit drug 
use and alcohol consumption associated with neonatal 
outcomes
Reynolds CME, Egan B, Daly N, McKeating A, Sheehan SR and 
Turner MJ (2019) Journal of Public Health, Early online.
https://www.drugsandalcohol.ie/30260/
The adverse effects of smoking on neonatal outcomes, such as 
small-for-gestational-age (SGA), has been extensively studied; 
however, the consequences of smoking combined with alcohol 
and/or drug use is less clear.
Illicit drug use combined with maternal smoking during 
pregnancy increases the risk of adverse neonatal outcomes 
above that of smoking in isolation.
‘Do as we say, not as we do?’ the lifestyle behaviours of 
hospital doctors working in Ireland: a national cross-
sectional study
O’Keeffe A, Hayes B and Prihodova L (2019). BMC Public Health, 
19(1): 179. 
https://www.drugsandalcohol.ie/30293/
This study was conducted to assess the lifestyle behaviours of 
a national sample of hospital doctors working in Ireland. We 
also sought to compare the prevalence of these behaviours in 
doctors to the general Irish population.
While the prevalence of health behaviours amongst hospital 
doctors in Ireland compares favourably to the general 
population, their alcohol consumption and engagement 
in health enhancing physical activity suggest room for 
improvement. Continued health promotion and education on 
the importance of personal health behaviours is essential.
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The experience of the treatment demand indicator in 
Europe: a common monitoring tool across 30 countries
Montanari L, Pirona A, Guarita B, Hedrich D, Mounteney 
J and Vicente J (2019) Journal of Studies on Alcohol and 
Drugs, Suppl 18: 139–151.
https://www.drugsandalcohol.ie/30226/
The article describes an epidemiological indicator called 
Treatment Demand Indicator (TDI). The TDI aims to provide 
professionals and researchers with a common European 
methodology for collecting and reporting core data on 
drug users in contact with treatment services. The article 
discusses the implementation of the TDI in the European 
countries and describes the main results, limitations, and 
future perspectives.
The TDI is the largest drug dataset in Europe, and its data 
is increasingly used in European and national data analysis. 
The use of a common drug-treatment-monitoring tool 
across a group of countries provides a useful instrument 
for policymakers, professionals, and managers working in 
the drug treatment field.
Patterns of self-harm methods over time and the 
association with methods used at repeat episodes of 
non-fatal self-harm and suicide: a systematic review
Witt K, Daly C, Arensman E, Pirkis J and Lubman D (2019) 
Journal of Affective Disorders, 245: 250–64.
https://www.drugsandalcohol.ie/30259/
The risk of self-harm repetition and suicide may be 
influenced by self-harm method choice. However, there 
are mixed findings regarding whether there is a discernible 
pattern in self-harm methods over successive episodes 
of non-fatal self-harm, and if so, how these may be 
associated with self-harm repetition and/or suicide.
Given the frequency of method switching observed, 
and the lack of discernible patterns over time, all 
patients should be routinely assessed for risk and needs 
irrespective of the method used at the index episode of 
non-fatal self-harm.
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9 Recent publications continued Appraisal of international guidelines on smoking cessation 
using the AGREE II assessment tool
Quintyne KI and Kavanagh P (2019) Irish Medical Journal, 112(2): 
867.
https://www.drugsandalcohol.ie/30258/
The aim of this study was to identify and evaluate the quality of 
methodological rigours and transparency used in guidelines for 
smoking cessation (for specific groups including: general adult 
population; persons with mental illness; and pregnant women).
Our findings have demonstrated higher scores among the most 
recent guidelines, reflecting improvement in the quality of 
guideline development over time. Methodology and editorial 
independence were particular concerns and this assessment 
also highlighted a need for contextualisation to the Irish 
healthcare system. In conclusion, the plan for Ireland is to 
adapt rather than simply adopt existing guidelines.
Implementation of a quit smoking programme in community 
adult mental health services – a qualitative study
Burns A, Webb M, Stynes G, O’Brien T, Rohde D, Strawbridge J, 
et al. (2018) Frontiers in Psychiatry, 9: 670.
https://www.drugsandalcohol.ie/30227/
This study aimed to review the implementation of a smoking 
cessation programme across 16 community mental health day 
services.
In conclusion, although this group-based cessation programme 
in community mental health settings was well-received overall, 
a number of key barriers persist. A joined-up approach which 
addresses the culture of smoking in mental health settings, 
inconsistencies in smoking policies, and provides consistent 
cessation support is needed. Care needs to be taken with 
the timing as overall it may not be helpful to introduce a new 
smoking cessation programme at the same time as a tobacco 
free policy.
